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I. OBJECTIVES 
Solid-organ transplantation for the treatment of patients with end-stage organ failure 
has been one of the most exciting medical advances in the 20th century. The number of 
patients awaiting transplantation has been increasing due to advances in immunosuppression 
while there is no good solution to expand the number of donors and to increase the number of 
transplantations. One possibility to ease the need for renal transplantation is to increase the 
life span of grafts. Better maintenance therapy as well as earlier diagnosis and effective 
treatment of rejection can save allografts by minimizing damage.         
 Evidence from several transplant centers has indicated that a substantial 
proportion of acute and chronic renal allograft rejection processes is caused by antibodies 
reactive to donor antigens. Antibody mediated acute rejection (AMR), a newly described 
entity, arises despite ongoing therapy with potent anti-T cell pharmacological agents. My 
thesis, which is based on the literature and our own experience, elucidates the mechanisms of 
AMR as well as novel diagnostic and therapeutic approaches to avoid, recognize and treat 
acute antibody mediated rejection. In our work, we have explored the factors influencing the 
occurrence of AMR and the useful methods and markers for diagnosing it. We have sought to 
compare the outcomes of a plasmapheresis (PP)-based versus a PP plus rituximab regimen to 
treat patients experiencing AMR and resistant to steroid plus anti-lymphocyte globulin 
treatments. 
  Post-transplant malignancy has become an important cause of mortality since newer, 
more potent immunosuppressive regimens have steadily reduced the incidence of acute 
rejections extending the life of allografts. My work also investigates possibilities to reduce the 
number and to manage post-transplant malignancies, particularly post-transplant 
lymphoproliferative disease (PTLD) a major complication of post-transplant 
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immunosuppression. In this thesis I have elucidated the efficacy of rituximab to encounter B-
cell related processes such as AMR and PTLD.  
However, while outcomes following transplantation have improved over the years, 
allograft loss is a problem ultimately confronted by many recipients. For such patients, repeat 
transplantation often provides the best chance for survival and good health. While re-
transplantation offers hope, previous studies have demonstrated that outcomes following 
repeated transplantation are, in general, inferior to those observed with first transplants [1]. 
We have also investigated the influence of demographic and immunological factors on the 
patient and graft survivals as well as occurrence of acute and chronic rejections among 
primary and re-transplant patients.  
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II. ANTIBODY MEDIATED REJECTION, A NEWLY DESCRIBED ENTITY 
 
II/1. Introduction 
 Sir Peter Medawar’s pioneer work brought together surgery and immunology, and 
gave ‘hope of progress’ to the clinical application of tissue and organ transplantation. At the 
beginning of World War II, treatment of burns patients had led him to the recognition of skin 
allograft rejection. The treatment of a badly burned patient was carried out using a 
combination of ‘pinch’ grafts taken from the patient herself (autografts), and those from 
another unrelated individual (allografts in current parlance). In addition, a second set of grafts 
was later transplanted from the same donor. The grafts were observed visually and, following 
appropriate biopsies, histologically. Surprisingly, this was the first systematic study of the 
process of rejection. The results showed that rejection of the first set of allografts was 
preceded by a latent period, with healing-in and vascularization indistinguishable from the 
autografts. However, rejection of the second set of allografts from the same donor took place 
much more rapidly, a hallmark of an immune response. These results established that the 
underlying basis of skin allograft rejection could be regarded as immunological rather than 
due to surgical problems or vague physiological incompatibilities [2]. He took this 
investigation further in experiments performed on outbred rabbits, confirming the specificity 
of second set rejection of grafts from the same donor as the first, and determining that graft 
rejection was preceded by an intense infiltration of lymphocytes [3]. 
 The degree of immune response to a graft depends on the genetic disparity between 
the grafted organ and the host. Xenografts, which are placed between members of different 
species, show the greatest disparity and elicit the maximal immune response, undergoing 
rapid rejection. Autografts, which are grafts from one part of the body to another (eg, skin 
grafts), are not foreign tissues and, therefore, do not elicit rejection. Isografts, which are grafts 
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between genetically identical individuals (eg, monozygotic twins), also undergo no rejection. 
Allografts are grafts between members of the same species that differ genetically. This is the 
most common form of transplantation. The degree to which allografts undergo rejection 
depends on the degree of histocompatibility between donor and recipient. The degree and type 
of response also vary with the type of the transplant. Some sites, such as the anterior chamber 
of the eye and the brain, are immunologically privileged (i.e., they have minimal or no 
lymphatics or vascularity, respectively); they tolerate the presence of mismatched grafts. In 
contrast to skin grafts which are not initially vascularized and so do not manifest rejection 
until the blood supply develops, the heart, kidneys, and liver are highly vascular organs 
producing vigorous immune responses in the host.  
The antigens responsible for rejection of genetically disparate tissues are the products 
of histocompatibility genes which encode more than 40 loci. The loci responsible for the most 
vigorous allograft rejection reactions are located within the major histocompatibility complex 
(MHC). In man the system is denoted as human leukocyte antigen (HLA). In addition, minor 
histocompatibility antigens may also cause allograft rejection, as shown by the occurrence of 
rejection episodes among transplants exchanged between HLA-identical human donor and 
recipient pairs, although effective immunosuppression generally vitiates these responses.  
The immune response to a transplanted organ consists of both cellular (lymphocyte 
mediated) and humoral (antibody mediated) mechanisms. The detection and treatment of 
allograft rejection has historically focused upon T-cell mediated process including natural 
killer cells, macrophages, antigen presenting cells (APC), antigen specific cytotoxic T-cells 
(CD 8 pos.), T helper (CD4 pos.) cells, cytokines. Cell mediated immunity has been 
extensively studied and long considered to be the main effector during acute allograft 
rejection. In fact, current induction and maintenance immunosuppression protocols seek to 
target T lymphocytes and to lesser degree, APCs [4]. Conversely, the role of alloantibodies in 
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acute rejection episodes has been far less clear, although the adverse effects of a positive 
cytotoxic antibody pre-transplant crossmatch - hyperacute rejections - have been recognized 
for 40 years. In my thesis I have dissected the mechanism, diagnosis and therapy of AMR. 
II/2. Definitions 
 Multiple imprecise terms have been used to describe a rejection that may have a 
humoral component: vascular rejection, humoral rejection and accelerated acute rejection. 
The term antibody-mediated rejection (AMR) was eventually recommended [5] to describe all 
rejection reactions involving donor-specific antibody (DSA) or donor reactive antibodies, e.g. 
toward non-donor foreign anti-human leukocyte antigens (HLA), ABO isoagglutinins, and 
anti-endothelial antibodies. The spectrum of injury resulting from AMR includes hyperacute 
rejection occurring within two days after transplantation in patients with high levels of 
unrecognized DSA, as well as acute AMR generally occurring within the first weeks after 
transplantation sometimes later following an anamnestic increase in DSA activity in 
previously sensitized recipient. Chronic endothelial injury as a result of long term exposure to 
anti-HLA antibodies represents the other end of the spectrum - chronic AMR.  
Hyperacute AMR is rare nowadays because of the sensitive crossmatch technique 
using recipient serum with donor lymphocytes. The modern crossmatching techniques, such 
as flow cytometry crossmatch, are capable of revealing even a low grade immunization.   
Despite this sensitivity analyses with coated beads, save for avoiding HLA 
specificities to which antibody has been detected by routine serum screening, may be 
misleading due to insensitivity of the assay or altered antigen display on the particle 
producing a false negative result.  
However, the subsequent development of acute antibody mediated rejection cannot be 
detected pre-transplant despite the improved understanding of cellular and humoral immune 
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mechanisms and the new immunosuppressive drugs. AMR rather than T cell-mediated 
variants has become the major hazard for long-term graft survival. Among the 8 to 10% of 
subjects who experience AMR, recognized due to a recent modification of the Banff 
classification [6], [7] 27 to 40% experience graft loss [6, 8]. Among all episodes of acute 
rejection, 20 to 30% show features of AMR [6]. This disorder is characterized by a sudden 
onset of rapidly progressive allograft dysfunction, which typically occurs within 3 weeks after 
transplantation [6],[9]. However, AMR may occur months or even years thereafter, 
particularly in the settings of non-adherence to the therapeutic regimen or altered absorption / 
metabolism of immunosuppressive drugs [6], [10]. 
II/3. Mechanisms of antibody mediated rejection 
AMR results from the interaction of anti-donor antibodies, which are either preexistent 
at low titer or developed de novo after transplant, with allograft vascular endothelium [11, 
12], the interface between the intravascular and extravascular compartments which is essential 
for proper renal function. Traffic of macromolecules, solutes, plasma proteins and cells 
between these compartments is tightly regulated, and depends on the integrity of the 
endothelial cell layer.  
The intact endothelial surface is negatively charged, in part due to expression of 
electronegative molecules such as heparan sulfate. This electronegativity serves to repel 
negatively charged plasma proteins, including albumin and coagulation factors [13].  
In humans, all endothelial cells constitutively express class I antigens. The capillary 
endothelium, but not the arterial endothelium, can express both class I and II antigens [14]. 
According to the humoral theory of organ transplantation, binding of antibodies to endothelial 
cell antigens can finally cause damage via four pathways (Figure1., Cai and Terasaki [12]. 
Briefly, it can be mediated directly by complement via forming membrane attack complex or 
inflammatory cells recruited by soluble complement fragments, or by phagocytes that 
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recognize complement fragments deposited on endothelial cells via complement receptors. 
The finding of complement fragment C4d in rejecting graft capillaries provided strong 
evidence to support this theory [15]. Antibody-dependent cell toxicity may also play a role in 
mediating endothelium damage without the involvement of complement [16]. Secondary 
pathological changes after endothelium damage include platelet activation and thrombosis, 
endothelial and smooth muscle cell proliferation, and humoral and/or cellular infiltrates 
mediated direct organ damage.  These series processes contribute to thrombosis and vascular 
occlusion; therefore, the organ suffers irreversible ischemic injury. 
The interactions of endothelial cells with DSA may activate complement  causing cell 
lysis, loss of barrier integrity and subsequent ischemic injury [17]. The formation of 
intercellular ‘gaps’ and shedding of heparan sulfate molecules leads to loss of cell-surface 
electronegativity exposing the subendothelial matrix to plasma coagulation factors and 
platelets, resulting in thrombosis [18]. In addition to complement-mediated allograft injury, 
exposure to MHC class I antibodies induces vascular endothelial cell apoptosis, which is 
visible upon ultrastructural studies of human allografts experiencing acute AMR [19]. This 
phenomenon which occurs within days is complement independent. MHC class I antibodies 
may alter fibroblast growth factor receptor expression, thereby potentially inducing harmful 
proliferative changes [20]. Thus, variable levels of DSA activity may result in allograft injury 
through a variety of mechanisms, including both complement-dependent and independent 
pathways resulting in necrosis as well as endothelial cell apoptosis. This sequence of events 
provides logical targets for intervention in treatment of acute AMR. These interventions 
include lowering DSA activity through physical removal or inactivation as well as decreasing 
the production of DSA and complement inhibition. 
 In a prospective trial, it has already been found that by using antibody screening tests 
with flow cytometry or enzyme-linked immunosorbent assays, about 14%–23% of transplant 
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recipients with functioning grafts have detectable human leukocyte antigen (HLA) antibodies 
[21]. Within a 1-year follow-up period, 21 (8.6%) of 244 antibody-positive patients 
experienced graft rejection, which has significantly higher than the rate observed among the 
HLA antibody–negative patient group (43/1421 (3%,); p= 0.00003). These data suggest that 
some transplants may still function well in the presence of alloantibodies, which might be 
because of compensatory reactions of the transplanted organ to tissue injury. However, the 
graft may finally be rejected when the tissue repair system cannot fully compensate for the 
antibody-mediated injury. This damage-repair-damage process could take years to result in 
irreversible graft loss. This hypothesis has been supported by the study of Lee et al., who 
found that in some patients, it took many years for antibody-positive transplants to finally be 
rejected [22]. 
 Due to proper patient selection and the highly effective immunosuppressive drug 
therapies unlike hyperacute rejection, acute and chronic graft function loss may not result 
mainly from thrombosis-related rapid vascular occlusion. Instead there is more likely to be a 
progressive damage-repair-damage pathological process, the speed of which depends on three 
factors: the level of alloantibodies; the capability of the transplanted organ for tissue repair; 
and the immunosuppressive and other supportive therapy. 
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Figure 1. Mechanisms of AMR 
II/4. Development of donor-specific antibodies 
 Following presentation of donor HLA antigens and in the presence of stimulatory 
cytokines corresponding clonotypic CD20+ B lymphocytes response internalize, process and 
subsequently express donor antigen-derived peptides complexed to cell surface MHC class II 
molecules (Figure 2, Gloor et al.[11]). The antigen - MHC II complex is then presented to 
helper T lymphocytes, which respond by releasing cytokines that stimulate proliferation and 
differentiation of B-cells into antibody-secreting plasma cells. This sequence of events 
requires the interaction of co-stimulatory molecules expressed on both B- and T-cells, 
including CD40 and CD40L (CD154) [23]. Additionally, B lymphocytes respond to T-cell 
help by migrating to lymphoid follicles, forming germinal centers and subsequently 
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undergoing mutations in cell surface immunoglobulin, resulting in the production of new 
clones of cells secreting antidonor antibodies (Figure 3, Gloor et al. [11]). Clones possessing 
increased specificity for their antigen are conserved, while less-specific clones are deleted. 
The costimulatory interactions between B-cell CD40 and T-cell CD40L are essential for 
isotype switching, whereby immature B cells expressing IgM and IgD differentiate into 
elements producing IgG, a more sustained immune reaction [11]. 
 
  
Figure 2.  The interaction of T and B lymphocytes in development of donor-specific 
antibody-secreting plasma cells. (A). B lymphocytes expressing CD20 bind, internalize, 
process and then express the processed antigen-derived peptide complexed with MHC II 
molecule. (B). Antigen-derived peptide:MHC II complex. (C). T:B-cell interaction, under the 
influence of the co-stimulatory pathway (CD40-CD40L) results in production of cytokines 
which stimulate B cell proliferation and differentiation into DSA-secreting plasma cells. From 
Gloor et al.[11] 
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Figure 3.  Production of donor-specific antibodies (DSA). Naïve B-cells (CD20+/27−) and 
memory B cells (CD20+/27+) located in secondary lymphoid tissue, when exposed to HLA 
antigen in the setting of appropriate T cell help either form germinal centers (GC) where they 
proliferate and differentiate into long-lived DSA-secreting plasma cells (CD138+/CD20−) 
which subsequently migrate to the bone marrow, or differentiate into short-lived DSA-
secreting plasma cells without forming germinal centers. Helper T cells are required to permit 
differentiation of B cells into anti-HLA antibody-secreting cells. From Gloor et al.[11] 
II/5. Humoral responses directed against non-human leukocyte antigens 
Putative pathogenic antibodies that are not directed against the HLA system were 
observed among recipients who rejected HLA-identical kidneys more than three decades ago 
[24]. The relevance of non-HLA-related humoral immunity was recently confirmed among a 
large cohort of renal allograft recipients from the Collaborative Transplant Study [25]. 
However, characterization of non-HLA antibodies remains difficult. The antibodies rarely 
appear to recognize alloantigens, but often are directed against autoantigens. Similar to some 
autoimmune diseases, non-HLA antibodies may be diagnostically useful but not necessarily 
effector mechanisms. For this reason, it is important to identify their antigen specificity and 
potential pathogenicity of these moietes for rejection or other forms of allograft injury.  
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Aside from ABO blood group antigens and the HLA class I and II antigens, 
endothelial cells express minor histocompatibility antigens. However, the suspected existence 
of a common polymorphic non-HLA system in endothelial cells has not yet been confirmed 
by biochemical identification of the relevant antigens. Although several assays have been 
proposed to detect these determinants none has achieved acceptance possible due to the 
apparent heterogeneity of the endothelial antigens and their vascular bed-dependent 
distribution [26].  
The evidence supporting a role for non-HLA antibodies against most common targets 
is based on observational trials performed in different aspects of solid-organ transplantation 
and experimental models. Among the other non-HLA antigens are the products of major 
histocompatibility complex class I chain-related gene A and gene B (MICA and MICB), 
which are highly polymorphic alleles that are closely linked to the HLA-B locus located on 
chromosome 6. In a recent study evaluating diagnostic posttransplant antibody tests in 
patients with renal allograft dysfunction, MICA did not correlate with C4d-positive rejection 
and the positivity was found in only one C4d-negative case of chronic allograft injury [27]. 
MICA/B apparently cannot fix complement, as C4d positivity is rare in MICA positive 
patients without anti-HLA antibodies. The antibodies may function as activating ligands that 
acts as potential target cells in the effector phase of natural killer (NK) cytotoxicity [28]. 
Antibodies against Angiotensin II type 1 receptor (AT1R-Abs) have been implicated 
as a trigger mechanism of non-HLA directed humoral rejection. AT1R is a seven 
transmembrane-spanning G-protein-coupled receptor including an extracellular, glycosylated 
region connected to the seven transmembrane-helices linked by three intracellular and three 
extracellular loops [29]. A recent study reported the presence of agonistic antibodies against 
the AT1R (AT1R-Abs) among 16 renal allograft recipients who underwent severe vascular 
rejection and malignant hypertension in the absence of anti-HLA antibodies [30]. AT1R-Abs 
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have also been associated with preeclampsia, malignant hypertension and occasionally 
seizures [31]. They experienced accelerated vascular rejection refractory to steroids and 
antilymphocyte antibody preparations despite transplantation of a “zero-mismatch” kidney. 
Rapid onset of malignant hypertension with seizures also accompanied the rejection process 
sometimes. Removal ofAT1R-Abs by plasmapheresis combined with pharmacologic AT1R 
blockade improved renal function and graft survival in AT1R-Ab positive patients.  
The identified AT1R-Abs belonged to complement-fixing IgG1 and IgG3 isotypes. 
Signal transduction studies employing IgG from transplant and preeclamptic patients 
implicate that genes regulated by AT1R-triggered transcription factors and not antibody-
induced complement-directed cytotoxicity may account for a dominant effector pathway of 
the vascular injury [32].  
In 40% to 50% of cases renal allograft biopsies showing severe vascular changes such 
as fibrinoid necrosis were C4d negative, implicating involvement of noncomplement-fixing 
antibodies or other mediators [33]. Non-HLA antibodies may mediate many biologic 
processes leading to obliteration of small and large vessels due to inflamation, thrombosis and 
facilitation of cell growth/migration. Nevertheless, there remains a great deal of investigation 
to achieve a more precise definition of the antigenic targets and suitable assays for non-HLA 
antibodies. 
II/6. Clinical relevance of antibody-mediated processes 
Patients with less than 10% panel-reactive antibodies show a significantly longer half-
life than subjects with greater levels of sensitization [34], suggesting that pretransplant 
alloantibody levels are relevant to graft outcomes. While high levels of antibodies result in 
irreversible rejection, patients with lower levels of sensitization may experience rejection 
processes, although the graft may finally be rejected overcoming simultaneous tissue repair. 
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Hyperacute rejections continue to occur, according to The United Network for Organ 
Sharing (UNOS) kidney transplant registry particularly proportionate to increasing levels of 
panel reactive antibody (PRA) [35]. While it is unlikely that the crossmatch test was 
performed incorrectly, or that the test results were ignored or miscommunicated, there are 
other more likely reasons – antibodies directed against epitopes not arranged on lymphocytes 
or subclinical antibody levels. In contrast the presently applied FACS methodology may 
detect irrelevant antibodies that bind to lymphocytes but are unable to initiate graft 
destruction. The one-month failure rate 33% (n=52) among patients who were transplanted 
with a negative cytotoxicity crossmatch (that detects antibodies using complement-mediated 
target-cell killing) but a positive flow cytometry crossmatch was substantially greater than the 
8% rate among 179 flow cytometry negative patients [35]. The UNOS registry revealed 
greater incidence of primary non-function correlated with increasing levels of preformed HLA 
antibodies [36], suggesting  the involvement antibodies [35]. Many instances of primary 
kidney non-function, as evidenced by removal without ever functioning (8% of 7788 first, 
14% of 1471 second and 20% in 224 third grafts in the UNOS registry) were caused by 
‘hidden’ hyperacute rejection [35].  
Among subjects with rejection episodes far fewer patients were without versus with 
HLA antibodies pretransplantation (n=98) or post-transplantation (n=98) [37]. Both acute 
humoral and acute cellular elements of rejection were observed among patients who displayed 
antibodies.  
II/7. Diagnosis of AMR 
In addition to its fulminant clinical course, AMR is characterized by evidence of antibody 
deposition in the kidney as evidenced histologically by accumulation of neutrophils in 
glomerular and peritubular capillaries, by vasculitis or by fibrinoid necrosis of arteries and 
arterioles. Accumulation of polymorphonuclear neutrophils and monocytes/macrophages in 
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dilated cortical peritubular capillaries (PTC) is suggestive of acute humoral rejection [38-44]. 
Other pathological features include as glomerulitis with neutrophils and/or monocyte 
infiltration, glomerular and arteriolar fibrin microthrombi and severe vasculitis with fibrinoid 
necrosis (Figure 4). However, these morphological features alone do not provide a specific 
and sensitive diagnosis. 
 
Figure 4. Acute humoral rejection. (A) Peritubular capillaries contain numerous 
polymorphonuclear leukocytes and mononuclear cells. Glomerular capillaries contain some 
polymorphonuclear leukocytes and mononuclear cells and a fibrin thrombus. (B) Insert of A, 
left-middle part. Numerous polymorphonuclear leukocytes are observed in a peritubular 
capillary. Interstitial oedema is noted. Periodic acid-Schiff (PAS)-staining; original 
magnification ×200(A) and ×500 (B). (C) Immunofluorescence microscopy using monoclonal 
antibody to C4d. Intense linear circumferential staining of the peritubular capillaries (Fresh 
frozen tissue sample. Original magnification ×250). (D) Immunohistochemistry using 
polyclonal antibody to C4d. Intense staining of the peritubular capillaries (Paraffin-embedded 
tissue. Original magnification ×480). From: Moll and Pascual Humoral rejection of organ 
allografts Am J Transplant 2005;5(11):2611-2618.[14] 
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A more specific diagnosis of AMR is deposition of complement-dependent moieties 
(Figure 4) that leave a footprint of diffuse C4d deposition along peritubular capillaries (PTC), 
[6, 9, 45, 46] C4d deposition in peritubular capillaries has been demonstrated to be a useful, 
sensitive marker for diagnosing AMR. This observation correlates with poor allograft survival 
[46, 47]. The prognosis of renal allografts demonstrating early post-transplant capillary C4d 
positivity was found to be significantly worse, with a 1-year graft survival of only 57% and 
63% (diffuse and focal C4d deposition respectively), as compared to a 90% 1-year graft 
survival among kidneys without C4d deposits [46]. Although this study performed in the 
‘cyclosporine, steroids, azathioprine’ era was confirmed using materials from the current era 
of newer immunosuppressive agents [6, 43, 48]. Moreover, the adverse predictive value of 
capillary C4d deposition has been shown to be independent of numerous other morphological 
and clinical factors [49]. 
 Experimental animal studies have also suggested the role of complement in AMR. 
Complement fixation is shown to promote acute or hyperacute rejection [50]. Complement 
fixing isotypes of monoclonal anti-H-2 class I antibodies passively transferred the AMR 
toward mouse cardiac allografts [51], a reaction that was associated with C4d deposition in 
the microvasculature. These findings were similar to those observed among renal and heart 
grafts in humans [52, 53]. C4d is relatively durable due to the covalent bond to tissue element 
(C4d contains an internal thioester bond). In mice the C4d depositiob disappeared two weeks 
after passive transfer [52] and five days after the rat heart was re-transplanted back into an 
isogeneic recipient [53]. The acute effects of complement are well described and include 
chemoattraction of neutrophils and macrophages via C3a and C5a, vasospasm through the 
release of prostaglandin E2 from macrophages, and edema through the release of histamine 
from mast cells. C3a and C5a increase endothelial adhesion molecules, E-selectin, vascular 
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cell adhesion molecule-1 and ICAM-1, and production of cytokines and chemokines such as 
IL-6, IL-1α, CXCL8, and CCL5. The membrane attack complex, C5b-9, causes lysis of ECs. 
The local production of complement components, such as C6 by recipient macrophages, 
augments acute rejection. Protection from antibody-mediated rejection can be achieved in 
animal hosts by inhibition of the complement system, as shown by transgenic expression of 
the complement regulatory proteins CD46 (membrane cofactor), CD55 (decay-accelerating 
factor), and CD59 in pigs [54]. High expression of transgenic human CD46 prevented 
hyperacute rejection and thrombotic manifestations. 
Mauiyyedi at al. performed a prospective study to evaluate the value of C4d staining 
for the diagnosis of AMR. 67/232 kidney transplanted patients developed acute rejection 
within the first 3 months among all acute rejection biopsies. Widespread C4d staining in PTC 
was present in 30% (20/67). A second metric of AMR is DSA which were present in 90% of 
the C4d+ cases (18/20) compared with 2% (1/47) of the C4d-  acute rejection cases (P 
=0.001). The sensitivity for the diagnosis of AMR of C4d staining was reported to be 95% 
versus 90% for donor-specific antibody tests [6].  
Another index of humoral activity is the presence of putative donor-specific antibodies 
directed toward Class I or Class II human leukocyte specificities [6, 39, 55], as detected with 
HLA antigen-coated beads by flow cytometry. However, HLA class II-reactive antibodies are 
not always detected in conventional microtoxicity assays using panel cells, and may require 
more refined techniques (i.e. flow cytometric crossmatching and/or HLA antigen-coated 
fluorescent microparticles) [56-58]. The diagnosis of AMR has been aided considerably by 
technologic advances in histocompatibility testing and immunohistology. The increased 
sensitivity of assays and the ability to distinguish between antibody specific for the donor 
versus antibody to third-party HLA antigens or non-HLA antigens have been tremendous 
advancements [59, 60]. DSAs have been reported to be present in the majority of patients 
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whose renal biopsies are C4d positive. Despite the absence of vascular abnormalities, grafts 
with typical histological features of cell-mediated rejection may display a humoral component 
as evidenced by the C4d deposition [6, 9].  
A firm diagnosis of AMR can be estabilished when there is the presence of allograft 
dysfunction, characteristic histology features, presence of C4d and DSA. However, all of 
these data are not always available, and there may be a dangerous time to acquire this 
information.  
Figure 5 shows an algorithm for the diagnosis of acute AMR caused by anti-HLA 
antibodies. The initial branch point in the algorithm is defined by the presence or absence of 
graft dysfunction. If graft dysfunction is present, the next step assesses the level of risk 
associated with the clinical setting of transplantation. 
 
Figure 5. Algorithm proposed by the Antibody Working Group for the diagnosis of antibody-
mediated rejection (AMR). From: Montgomery, Transplantation, 2004;78(2):181-185 [5] 
High-risk criteria include husband to wife or child to mother donor-recipient pairs, 
history of a sensitizing event (pregnancy, transfusion, or previous transplant), and known 
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production of HLA-specific antibody, current or historicall. If the transplant has occurred in a 
low-risk setting, there is greater a burden of proof for the diagnosis of AMR requiring both 
biopsy findings as well as the presence of DSA. In high-risk patients, the presence of 
characteristic features of AMR on light microscopy with (+) C4d staining represents sufficient 
diagnostic criteria. Even without DSA or characteristic biopsy features, one must maintain a 
high index of suspicion for AMR among patients with significant risk factors who show graft 
dysfunction [5]. 
In the absence of clinical graft dysfunction, routine biopsy or detection of DSA may 
suggest positive findings. The significance of these events remains incompletely elucidated. 
Light microscopic features consistent with AMR may appear on protocol biopsies obtained 
from patients with stable renal function, suggesting a subclinical or a preclinical antibody-
mediated process that may or may not evolve into frank AMR. If DSA is detectable and there 
is evidence of injury on biopsy in the acute setting, graft dysfunction will likely occur. These 
patients may benefit from early or preemptive treatment seeking to eradicate the DSA or 
resolve the injury. In cases of ABO incompatible grafts, it is not unusual to see C4d staining 
without histologic evidence of injury [61]. This may represent accommodation, and it is 
unclear whether this findings warrants treatment, especially when isoagglutinin titers are 
stable. Anti-HLA DSA may be detected despite of a normal biopsy and unchanged graft 
function. This could also represent accommodation or a latent antibody response. In the early 
posttransplant period this may be an appropriate trigger for therapy. In most cases anti-HLA 
DSA can be durably suppressed except for ABO isoagglutinins in which antibody may return 
with adverse consequences. 
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II/8. Treatment of AMR 
Traditional anti-rejection treatments, such as administration of steroid boluses or anti-
lymphocyte antibodies are usually ineffective to treat AMR, since these modalities are 
primarily directed toward cellular immune mechanisms. Among the biopsies obtained to 
diagnose acute rejection episodes, 12-37% has been reported to occur in patients resistant to 
standard therapies; they experience a poorer prognosis [62]. Approaches to treat AMR seek to 
remove deleterious antibodies using plasmapheresis (PP) or immunoadsorption, and to modify 
B cell activation and antibody generation by administration of intravenous immunoglobulin 
(IVIg; 1 to 2 g/kg) or low-dose CMV hyperimmune globulin (100 mg/kg) [5, 6, 63-71] and to 
eliminate B-cells with rituximab (375 mg/m2;[72]) .  
II/8.1. Primary immunosuppressant  
While almost all currently used immunosuppressive drugs have direct or indirect 
effects to inhibite/deplete B cells. The most commonly used primary agents of maintenance 
immunosuppression, such as cyclosporine A, tacrolimus, and sirolimus, are powerful 
immunosuppressants that interfere with T-cell signaling. The successful prolongation of graft 
survival by using these agents has misled many clinicians and some immunologists into 
thinking that T cell is the only player that causes graft rejection. However, because many 
alloantigens eliciting antibody responses are proteins (e.g.,HLA, MIC) and antibody 
responses to protein antigens require antigen-specific T-cell help, T-cell targeting agents not 
only prevent T-cell but also antibody (B cell)-mediated immune responses. This mechanism 
explains why these primary agents may be used in combination with other therapies to treat 
antibody-mediated humoral rejection [12, 39]. 
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II/8.2. Adjunct immunosuppressants 
Unlike primary immunosuppressive agents, which block T-cell signaling and 
indirectly inhibit proliferation of B cell secondary to reduced cytokine production by T cell, 
adjunctive immunosuppressants interfere with nucleosid synthesis retarding cell division [73, 
74]: namely azathioprine, cyclophosphamide, mycophenolate mofetil (MMF). These agents 
have direct inhibitory effects on B cell, an active dividing tissue cell. It is notable that because 
of its role in targeting the de novo purine biosynthesis pathway, mycophenolates can inhibit 
human lymphocytes (B and T cells) more specifically and efficiently than other cell types 
[73]. Clinical observations have suggested that immunosuppressive protocols with MMF 
inhibited antibody production and reduced allograft rejection episodes [75, 76].  
II/8.3. Anti lymphocyte antibodies 
Antibodies against lymphocyte surface molecules actin concert with complement to 
remove specific lymphocyte subsets or to inhibite cell function [67, 77-79]. The anti-CD3 
reagent OKT3 blocks T-cell activation thereby inhibiting proliferation of naïve B-cells. 
Campath-1H which is directly reactive with CD52 surface marker on thymocytes, T and B as 
well as mast cells, directly depletes B-cells. Anti-thymocyte globulin (ATG) and anti-
lymphocyte globulin (ALG) interfere with T-cell help, and due to cross-reactivity reduce 
reduce and inhibit B-cells [12]. However, the anti T-cell effect of these reagents is so 
profound but they are unable to produce sufficient B-cell suppression to overcome a robust 
AMR. 
II/8.4. Rituximab  
II/8.4.1. Introduction 
Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Basel, 
Switcherland;  Rituxan, IDEC Pharmaceuticals, San Diego, CA, and Genentech, Inc, San 
Francisco, CA) is a genetically engineered, monoclonal, chimeric (mouse/human) antibody 
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directed against the B-cell surface marker CD20 [80]. It was approved in the United States in 
1997 and in the EU in 1998 only for the treatment of refractory or relapsed B-cell lymphomas 
[81]. After demonstration of its efficacy it was approved for the treatment of rheumatoid 
arthritis (RA) in 2006 by the FDA as well as the EU [82].  
Rituximab has been used “off label” to treat transplant patients in several settings 
primarily based upon non-controlled clinical experiences.  
1. post-transplant lymphoproliferative disorder;  
2. rejection prophylaxis; 
3. rejection reversal; 
4. conditioning for ABO incompatible transplantation; 
5. and desensitization in HLA sensitized patients. 
II/8.4.2. Pharmacodynamics and pharmacokinetics  
Rituximab comprises human IgG1Fck constant regions and Fab’2 small variable light 
and heavy chain regions of the murine anti-human CD20 antibody (IDEC-2B8). The construct 
was cloned into Chinese hamster ovarian (CHO) cells for the production of immunoglobulin 
[81]. Rituximab (molecular weight of 145 kDa) consists of two heavy chains (451 amino 
acids) and two light chains (213 amino acids). Its binding affinity for the CD20 antigen is 
approximately 8.0 nM [81]. Binding specificity for the CD20 antigen resides in the 
complementarily determining sequences with the variable murine regions, while the human 
portion triggers complement- and cell-mediated lysis mechanisms in vivo. 
The majority of pharmacokinetic and pharmacodynamic studies have been performed 
in patients with B-cell lymphoma [80, 83]. Nine patients presented who received four doses of 
375 mg/m2 as an IV infusion displayed a mean serum half-life of 59.8 hour (range=11.1 - 
104.6 hour) after the first infusion and 174 h (range 26 to 442 h) after the fourth infusion. The 
serum concentration correlated directly with the response and inversely with tumor burden. 
 
 
27
The wide range of half-lives was attributed to the variable tumor burden, especially the 
changes normal versus malignant B-cell populations upon repeated administrations. In a 
single-dose study in subjects with renal failure, a substantially longer half-life was observed 
ranging from 10 to 14 days [72]. In a study using rituximab for the treatment of rheumatoid 
arthritis, the half-life after the second dose was 20 days, which was similar to native IgG [84].  
II/8.4.3. Administration and adverse reactions  
The appropriate amount and the number of doses of rituximab are dependent on the 
clinical setting. For lymphoma, the approved dose is 375 mg/m2 as an IV infusion for four 
weekly doses. However a small single dose (50 mg/m2) study suggested similar efficacy with 
terms of degree and duration of peripheral B-cell suppression, and effect on antibody response 
[72]. In adult rheumatoid arthritis (and most autoimmune diseases) the suggested 
administration is two doses of 1 gm every other week [85], which is similar to the four-dose 
regimen in a 1.73 m2 adult. In this study body surface area was shown to contribute 19.7% to 
the variability in antibody clearance, an insignificant contribution to the variability in drug 
exposure as measured by AUC. Therefore, for adult rheumatoid arthritis, dosing by body 
surface area is not necessary. 
II/8.4.4. Clinical outcomes 
Garrett and colleagues reported a case of humoral rejection that was successfully treated 
with rituximab [77], followed by a series of 8 succesfully treated heart transplant patients 
[86]. A Wisconsin group successfully treated 27 patients who were diagnosed with biopsy-
confirmed rejection manifested with thrombotic microangiopathy and/or endothelialitis 
between February 1999 and February 2002. Twenty-four subjects received additional steroids, 
and 22/27 patients were also treated with plasmapheresis (PPH) and antithymocyte globulin. 
Only three patients experienced graft loss not associated with patient death during the follow-
up period (605+/- 335.3 days). Among the 24 successful patients, the mean serum creatinine 
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decreased from 5.6+/- 1.0 mg/dl at therapy initiation to 0.95+/-0.7 mg/dl at discharge. Authors 
predicted that the addition of rituximab may improve outcomes in severe, steroid-resistant or 
antibody-mediated rejection episodes after kidney transplantation [67]. A case report 
suggested that rituximab can be used successfully even in desperate, steroid and polyclonal 
antibody treatment resistant, C4d negative rejection episodes [87]. Among 8 renal transplant 
patients with C4d+ and DSA+ AMR treated with four infusions of rituximab (375 mg/m2 per 
week for four weeks) in addition to plasma exchange (2-17 sessions), steroids, mycophenolate 
mofetil and tacrolimus, Faguer at al. reported at a follow-up of 10 months (range 7-23), 100% 
and 75% patient and graft survivals, respectively. Renal function improved in 6 cases, graft 
loss occurred in two and four patients experienced infectious complications. DSA disappeared 
or decreased in four cases [8].  
Rituximab and intravenous immune globulin has also been used for pre-transplant 
desensitization. Ashley et al. achieved among 20 highly sensitized patients (PRA=77+/-19% 
or with DSA) 100% and 94% patient and graft survival rates, respectively. Time to transplant 
after desensitization was 5+/-6 months. After the second infusion of intravenous immune 
globulin the mean PRA level was 44+/8-30%. The authors concluded that a combination of 
intravenous immune globulin and rituximab may be an effective desensitization regimen for 
patients awaiting transplantation from a living or a deceased donor [88].   
The optimal off label use or dosage of rituximab for AMR has not yet been established. 
The low AMR rates observed using current immunosuppression make such trials hard to 
recruit, enforcing the need for cooperative multicenter trials with long term follow up. As 
rituximab has no effect on plasma cells and little effect on circulating antibody, it is likely to 
be most effective for the treatment of rejection in combination with other strategies that 
include plasmapheresis and/or intravenous immunoglobulin (IVIg) therapy.  
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The ultimate resolution of the dosing regimen is important if for no other reason than 
cost, since rituximab is expensive. As currently available the 10 mg/mL concentrate 
containing either 10 mL (100 mg, average wholesale price of $568) or 50 mL (500 mg, 
average wholesale price of $2840). If using body surface area dosing, for an average 1.73 m2 
person, the required dose is 650 mg, which would translate to $3976 per infusion or $15 904 
for four-treatments. If using the 1000 mg dose, it would be $5680, or $11 360 for the two-
dose course.  
As opposed to many chemotherapeutic agents, the does is adjusted for lung, kidney, 
liver, or heart dysfunction. It is recommended to premedicate patients with acetaminophen 
and antihistamine before each infusion to prevent reactions. Adverse reactions related to 
rituximab usually occur during the first administration. 
In the transplant setting corticosteroids are given in conjunction (e.g. treatment of 
rejection or at the time of transplant), the rate and severity of side effects is decreased. In 
rheumatoid arthritis patients, a single 200 mg dose of methylprednisolone with the first dose 
of rituximab did reduce the frequency of side effects [89]. 
Upon subsequent infusions, reactions are milder in intensity or do not arise at all [90]. 
Mild reactions can be treated symptomatically during the infusion: flu-like symptoms, fever, 
chills, rigors, nausea, headache, and rash. Agarwal et al. demonstrated increased cytokine 
levels particularly TNFα, immediately after the first dose of rituximab which can be 
associated with a febrile response [91]. Rare but more serious reactions include angioedema, 
hypotension, bronchospasm, and hypoxia can occur, usually within 30–120 min of beginning 
the first infusion. In these cases, rituximab should be stopped to initiate supportive care. After 
resolution of all symptoms, the infusion can be restarted at slower rate.  
As of 2004, over 540,000 patients had received rituximab world-wide [92]. In a few 
lymphoma patients, rituximab therapy resulted in major complications, including tumor lysis 
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syndrome, infusion-related death, mucocutaneous reactions, delayed neutropenia, and lung 
injury, but their incidence was 0.5% upon post-marketing safety data analysis [92]. As 
rituximab affects both malignant and non-malignant CD20-positive B cells, there are concerns 
about infectious complications from the therapy. However, patients receiving maintenance 
rituximab for non-Hodgkin lymphoma have not been reported to show an increased infection 
rate after 2 years of continuous B-cell suppression [93]. Protective titers against immunized 
pathogens appear to be preserved in most instances. 
Despite B-cell depletion for approximately 6 months, immunoglobulin levels in 
lymphoma patients remain stable after one cycle of rituximab treatment [94]. Extended use of 
the drug may result in decreased IgM levels [95]; therefore, measurement of serum IgG levels 
should be considered along with appropriate treatment with intravenous immunoglobulin if 
levels fall below 300 mg/dL [96].  
In patients treated with rituximab rare case reports have described hepatitis B virus 
(HBV) reactivation resulting in liver failure [97], fatal varicella-zoster infection [98], pure red 
cell aplasia because of parvovirus B19 [99] and reactivation of latent JC virus. Based on these 
reports and several phase II trials, patients with PTLD appear to tolerate rituximab as well as 
de novo lymphoma patients. Of note, reactivation of cytomegalovirus infections resulted in 
the death of one PTLD patient after rituximab treatment [100]. Those PTLD patients who 
have an increased risk of HBV infection should be considered for HBV screening test prior 
rituximab. 
Rituximab may be detected in the serum for many months after dosing [72]. The 
persistence of rituximab in the serum has implications for crossmatch and tissue typing 
analyses. These antibodies binding to B-cells could be detected using a second antibody 
suggesting the presence of alloreactivity. Since rituximab is cytotoxic in the presence of 
complement, sera that contain rituximab would produce a positive B-cell cytotoxic-positive 
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crossmatch. The human portion of the IgG1 can provide a target for the anti-human Ig 
fluorochromes in flow cytometric crossmatches again resulting in a false positive B-cell 
crossmatch. Flow and cytotoxic crossmatches and PRA determinations, however, can be 
attempted by either pronase treatment to reduce the cell surface CD20 or by removal of the 
circulating rituximab with immunomagnetic bead absorption [101]. 
II/8.4.5. Mechanisms of action  
CD20 is a B-cell surface antigenic phosphoprotein that is restricted in its expression to 
pre-B and matures B-cells. It is neither present on stem cells nor on plasma cells [8, 67], 
although plasma blasts and stimulated plasma cells may express CD20 [102]. It does not 
rapidly modulate upon binding with anti-CD20 antibodies [103]. Studies in patients with non-
Hodgkin’s lymphoma (NHL) have shown that rituximab treatment transiently and selectively 
depletes (CD20+) B-cells for up to six months. Thereafter, B-cell levels return to normal 
within 9–12 months [90]. Even when the total B-cell count returns to normal, there appears to 
be a change in the phenotype, with the B-cells present being relatively deficient in expression 
of CD27, a surface marker of memory B-cells [104], suggesting that the repopulating B-cells 
are primarily naive, at least as 2 years after a single dose.  
CD20 does not shed, modulate or internalize after antibody binding; its expression is 
stable [105]. Anti-CD20 antibodies therefore remain bound to CD20 on the cell surface, 
where they initiate cell lysis. Free CD20 antigen is not found in the circulation [106].  
There are no known natural ligands for CD20. The function of CD20 seems to be 
involved in the regulation of B lymphocyte growth and differentiation, possibly playing a role 
in Ca2+ influx across plasma membranes to maintaine intracellular Ca2+ concentration 
ncessary for B-cell activation [107]. The following effects of rituximab may contribute to its 
B cell depletion properties [103]:  
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1. Antibody dependent cell mediated cytotoxicity (ADCC, Figure 6), in which natural  
killer cells, macrophages, and monocytes are recruited through their Fc receptors 
bound to surface CD20. This induces CD20+ B cell lysis [108, 109].  
 
 
 
Figure 6. Rituximab-mediated ADCC and strategies to enhance the ADCC effect.  
From: Zhou et al. The role of complement in the mechanism of action of rituximab for B-cell 
lymphoma: implications for therapy. Oncologist 2008;13(9):954-966. [110] 
Complement dependent cytotoxicity (CDCC) normally has little efficacy in 
rituximab therapy. This kind of cellular cytotoxicity can occur after binding of either 
the rituximab Fc region (in ADCC) or C1q, C3b, C4b, and iC3b (in CDCC) to their 
respective receptors, resulting in either phagocytosis or cell-mediated lysis of B-
lymphocytes, depending on the effector cell type. The Fc region of cell-bound 
rituximab is recognized principally by either activating receptors Fc-RI/ Fc-RIII or the 
inhibitory receptor Fc-RIIB, whereas the byproducts of complement activation are 
recognized by C1qR, CR1, or CR3 on effector cell surfaces. The strategies to 
overcome resistance to ADCC or CDCC effects and thereby enhance rituximab effects 
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include: (1) anaphylatoxins (C5a, C3a); (2) delivering of cytokines (IL-2, IL-12, M-
CSF) that activate effector cells; and (3) complement receptor 3 (CR3) - specific 
polysaccharides such as - glucan, which primes CR3 and therefore triggers cellular 
cytotoxicity [110].  
This theory is also supported by data from an animal model with the 
significance of Fc receptor-deficient mice, in which rituximab shows significantly 
diminished activity [109]. Further, it has been demonstrated that Fcγ receptor 
polymorphisms affect cellular affinity for the Fc portion of rituximab, thereby 
impacting the time to progression among rituximab treated follicular lymphoma 
patients. It has been long recognized that the response to rituximab and its impact on 
time to progression is variable among various lymphoma types and different patients 
of each type due to Fcγ polymorphisms [111, 112]. In the future determination of Fcγ 
R polymorphisms might be used to predict the a priori response to rituximab which 
has shown variable efficac [113, 114]. The ability to predict response would not only 
allow for a rational patient selection and cost-effective therapy but also would enable 
us to choose alternative therapies for those patients with high probability of treatment 
failure. New anti-CD20 antibodies or conjugates are being developed with re-
engineered Fc portions to enhance the efficacy of treatment by increasing binding 
affinity to Fcγ receptors [115]. 
2. Complement dependent cytotoxicity (Figure 7) is induced by complexed rituximab 
bound to surface CD20 and cousing C1q binding. Activation of the complement 
cascade and generation of the membrane attack complex, causing CD20+ B cell lysis 
[81]. C1q interacts with the rituximab Fc region exposed after binding to CD20 on the 
B-cell surface, thus activating the classical complement cascade and a membrane-
attack complex (MAC) is inserted into the cell membrane, with multiple MACs (12- to 
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16-mers) leading to cytolysis. Strategies to overcome resistance to CDC effects 
include: (1.) inhibitors of the membrane complement regulatory protein (mCRPs), 
decay-accelerating factor (DAF), especially CD59, which enhances complement 
activation and augments MAC formation on the cell surface; (2) heteroconjugates of 
rituximab to cobra venom factor (CVF) or C3b, and other antigen-antibody complexes 
targeting tumor cells, which enhance complement activation; and (3) drugs that 
upregulates CD20 expression, namely the histone deacetylase inhibitor trichostatin A 
or the protein kinase C activator bryostatin- 1 [110].  
hCD20 transgenic mice have been generated through the integration of 
bacterial artificial chromosomes encoding the hCD20 locus in FVB mice. In this 
murine model, hCD20 expression mimics that of humans yet the expression of the 
transgene occurs at a 50% level of that of circulating human B cells. 
 
 
Figure 7. Rituximab-mediated complement dependent toxicity (CDC) effect and strategies for 
enhancing the CDC effect. From: Zhou et al. The role of complement in the mechanism of 
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action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 
2008;13(9):954-966. [110] 
As this model preserved the CD20 epitopes recognized by rituximab, it is an 
invaluable tool to study the in vivo mechanisms of action of this drug [116].  Using 
this model, Gong et al. [116] have identified ADCC and CDCC as the most relevant in 
vivo depletional mechanisms of rituximab, and have shown that the susceptibility to 
depletion varies among the various lymphoid compartments. While CD20+ B cells in 
peripheral blood are rapidly depleted by rituximab [116], CD20+ B cells homing in 
lymphoid compartments are somewhat resistant to rituximab depletion, requiring 
longer, multiple-dose treatments to achieve effective killing. Of particular interest is 
the resistance to rituximab exhibited by B cells in the marginal zone (MZ). These cells 
are believed to be involved in natural antibody responses and maybe the sources of 
anti-ABO antibodies [116]) and germinal centers (GC) of the spleen [116, 117]. 
Depleting these cells is vital for the success of desensitization and antibody-mediated 
rejection protocols. MZ and GC B-cells are pivotal in the development of long-lived 
plasma cells and humoral responses against T-cell-dependent antigens [118]. Thus 
peripheral blood CD19 and CD20 absolute B-cell counts may not accurately reflect 
rituximab action. Although the assessment of lymphoid-bound B cells may be more 
accurate, this does not represent a clinically practical alternative. 
3. Rituximab has also been shown to induce CD20+ B cell apoptosis (Figure 8, [110, 
119]).  
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Figure 8. Rituximab-induced apoptosis in therapy and strategies to enhance apoptosis.  
From: Zhou et al. The role of complement in the mechanism of action of rituximab for B-cell 
lymphoma: implications for therapy. Oncologist 2008;13(9):954-966. [110] 
 
Phosphoproteins associated with glycosphingolipid-enriched membrane 
microdomains (GEMs) normally recruits Csk to maintain the Src-family kinases Lyn, 
Fyn, and Lck in an inactivated state. CD20–rituximab crosstalking can redistribute 
lipid rafts transactivating these kinases and initiating downstream signaling pathways 
resulting in apoptosis. The redistribution of lipid rafts may also induce apoptosis by 
Fas molecule clustering, which leads to the formation of death-inducing signaling 
complexes (DISC) with subsequent recruitment of Fas-associated death domain 
proteins (FADD) and caspase-8 into DISC, thereby activating the downstream 
apoptosis pathway. Meanwhile, the redistribution of lipid rafts can also inhibit p38 
mitogen- activated protein kinases (MAPK), extracellular signal–related kinases 
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(ERK-1/2), NFk-B, and Akt signaling pathways inhibiting both transcription and 
expression of many genes, particularly the anti-apoptotic genes Bcl-2, Bcl-xL, X-
linked inhibitor of apoptosis protein (XIAP), and myeloid cell leukemia sequence 1 
(Mcl-1), thereby making B-lymphocytes susceptible to apoptosis. In addition, 
inhibition of nuclear factor kappa B (NFk-B) pathway downregulates the transcription 
factor Yin Yang 1 (YY1), enhancing transcription of Fas and of death receptor 5 
(DR5) as well as facilitating FasL- and TRAIL-induced apoptotic cascade.  
Strategies to enhance apoptosis after rituximab treatment include: (1) 
scFvRit:sFasL (fusion protein); (2) mapatumumab, a humanized monoclonal antibody 
targeting tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptor 1; 
(3) a recombinant protein, Apo2L/TRAIL, all the above three drugs target DRs to 
trigger the apoptosis pathway; and (4) other means such as antisense oligonucleotides 
of related apoptotic molecules or bortezomib, a proteasome inhibitor that induces 
apoptosis. 
4. Rituximab exerts regulatory effects on the cell cycle that induce direct growth arrest. 
Bezombes et al. [120] demonstrated direct inhibition of growth by rituximab in Daudi 
and RL B-lymphoma cells in vitro. After moderate accumulation of tumor cells in the 
G1 phase, there was a significant loss of clonogenic potential without apoptosis. 
Rituximab produced a rapid, transient increase in acid-sphingomyelinase activity and 
concomitant cellular ceramide generation in raft microdomains, suggesting a 
ceramide-triggered signaling pathway associated with the induction of cell cycle– 
dependent kinase inhibitors such as p27Kip1 through an MAPK-dependent 
mechanism. Therefore, rituximab can mediate direct growth arrest, which may 
contribute to its anticancer activity. 
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5. B cells are efficient antigen-presenting cells, particularly after they have been 
activated [121]. Such activation could occur at the time of rejection. Rituximab may 
mitigatethis mechanism amplification. In addition loss of antigen presentation may 
reduce T-cell stimulation due to elimination of B-cell produced cytokines. Supporting 
the direct role of B cells in rejection is the report of Sarwal et al. showing that CD20 
gene expression was associated with a worse prognosis [122]. More recently, Hippen 
et al. showed that subjects with CD20 positive rejection showed worse long-term renal 
graft survival [123]. Of 27 patients with biopsy-proven Banff 1-A or Banff 1-B 
rejection in the first year after transplantation, 6 had CD20-positive B-cell clusters in 
the interstitium and 21 did not. The CD20-positive group displayed reduced graft 
survival compared to the CD20-negative controls. Rituximab treatment of a patient 
with such CD20 cells in the biopsy was succesful whereas the rejection had been 
resistant to steroids and anti-thymocyte globulin [124]. 
 
Possible mechanisms of rituximab action other than B-cell depletion: 
1. Increases MHC II and adhesion molecule expression: lymphocyte function-
associated antigens (LFA-1 and LFA-3) [125].  
2. Downregulates B-cell receptors and CD16 and upregulates CD54 on NK cells 
leading to their exhaustion [125].  
3.  Depletes DSA or inhibit their production, preventing the maturation of new DSA-
secreting plasma cells [126].  Since antibodies are primarily produced by plasma 
cells that have minimal expression of CD20 and therefore are not eliminated by 
rituximab, this mechanism has been questioned. However there is some debate 
whether plasma cells are long or short lived [127]. In the former case, a method to 
deplete plasma cells is needed, whereas in the latter, as CD27+ memory B-cells are 
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eliminated, and no source of alloantigen were present to re-stimulate newly 
appearing naıve B-cells, suggestingthat alloantibody titer and PRA will fall at a rate 
controlled by immunoglobulin half-life and the half-life of plasma cells. 
4. Down-regulates co-stimulatory B cell surface molecules expression, including CD40 
and CD23 [128].  
5. In some cases antitumor effects of rituximab persisted long after the antibody was 
cleared from circulation. These findings led some investigators to propose that 
rituximab-induced killing of malignant B-cells might result in priming of lymphoma 
antigen-specific T-cell responses in vivo. Generation of these T-cell responses or 
“vaccinal effects” of rituximab might in turn be responsible for an anti-lymphoma 
immunity that persists far beyond the initial cytotoxic effect of the antibody itself 
[129]. Supporting this mechanism, Selenko et al have shown that in vitro treatment 
of lymphomas with rituximab led to cell destruction and generation of apoptotic 
bodies processed by APCs with subsequent cross-presentation of tumor-derived 
antigens to T-cells [130]. It has been reported that rituximab administration may 
decrease the activated phenotype of peripheral and tissue-resident T-cells by 
abolishing antigen presentation by B cells, thereby enhancing the numbers and 
function of regulatory T cells leading to improvement in autoimmune disease [131]. 
6. Sience rituximab has been used for various indications (with the exception of 
lymphoma where the target cells are actually eliminated), it has been claimed that 
the reagent acts as a nonspecific intravenous immunoglobulin (IvIg) [132]. While 
the clinically used doses seem too low to cause an effect, recent data have suggested 
that IvIg inhibits anaphylatoxin-C3a and -C5a-induced calcium responses in vitro 
and blocks cellular migration and lethal C5a-mediated circulatory effects in vivo in 
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mice and pigs [133] at 10 mg/mL concentrations, which are less than observed at the 
peak of a rituximab infusion [72].  
II/8.4.6. Limitations 
Current therapy may be limited by exhaustion of immune effector mechanisms 
rendering the patient susceptible to overwhelming. For example, high burdens of IgG-
opsonized cells may deplete complement [134] and also exhaust cellular cytotoxicity 
mediated by NK cells and tissue macrophages [134, 135]. In contrast, ineffective rituximab 
therapy may lead to substantial reductions but not eliminationsof CD20 surface expression 
(shaving)[134]. Strategies to address these limitations include the development of novel anti-
CD20 monoclonal antibodies that more potently recruit effector functions, the use of lower, 
more frequent antibody doses, and the combination of antibody therapy with immune 
modifying drugs (IL2 or IL2 acitvated cells)  that mobilize or replenish effector 
functions[125]. Lessons learned from the strategies employed for CD20 immunotherapy may 
be useful for the optimization of other immunotherapeutic monoclonal antibodies such as the 
second-generation fully human, anti CD20 antibody namely ofatumumab [136].  
II/8.5. Splenectomy 
Splenectomy seeks to remove a major source of B-lymphocytes. Hume originally 
proposed this modality but Frye et al thought it to be more beneficial for re-transplant cases. 
The benefits of splenectomy to prolonge graft and patient survival remain controversial. 
Splenectomized patients displayed a reduced incidence and intensity of acute rejection 
episodes and better graft and patient survival rates in the azathioprine era [137]; however, this 
beneficial effect if anything was short-termed with various regimens. Recently, in 
combination with other treatment, splenectomy seems to play an important role to prevent 
humoral rejection and prolonging graft survival among ABO-incompatible transplantations 
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[138] although most current protocols have substituted rituximab treatment for the surgical 
procedure. 
II/8.6. Removal or blockade of preexisting or newly developed antibodies  
Methods to reduce or blocking their detrimental effects of existing antibodies include 
plasmapheresis and Immunoadsorption. The latter in vitro approach removes 
immunoglobulins from patient peripheral blood using blood group antigen A or B, protein A, 
or antihuman Ig-coated columns. Originally, it was primarily used as pre-emptive therapy for 
ABO-incompatible or presensitized patients [139-141]. But successful reversal of antibody-
mediated rejection has also been reported [42, 142, 143]. However; an HLA antigen column, 
which specialy removes HLA antibodies, is not yet commercially available. 
Plasmapheresis (PP) removes antibodies and other plasma factors such as 
complements and cytokines. It is an effective treatment for humoral rejection. Burns et al. 
recently reported pre-transplant PP of 41 B- or T-cell crossmatch positive patients who 
displayed high DSA levels and 29 with DSA content.  The incidences of AMR were 39% 
(16/41) in the High DSA group and 31% (9/29) in the Low DSA group. Overall the mean 
DSA levels decreased by day 4 post-transplant, remaining low in patients who did not develop 
AMR. By day 10, DSA levels increased in 92% (23/25) of patients developing AMR with 
positive B-cell flow cross-matches. The total DSA measured by single antigen beads 
correlated with responses suggesting that either could be used for monitoring. The authors 
concluded protocols that yielded lower level of DSA decreased the AMR incidence [144]. 
PP has also been used as a preemptive strategy to prevent potential rejection episodes 
[138, 145].  PP and/or IVIg have also been used to ‘desensitize’ highly sensitized patients in 
anticipation of living or deceased donor renal transplantation. Such strategies were successful 
in a number of individuals with positive crossmatches against their potential living donors or, 
who had been waiting for prolonged periods for a suitable deceased donor organ ([69, 146-
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148]. These modalities have also been used to reverse established antibody-mediated 
rejection, although they do not suppress antibody synthesis; which often rebounds after 
cessation of PP [67]. Abraham et al. reported 20/440 patients treated with PP alone with 
intensification of immunosuppressive regimen. Their approach to treat AMR was successful 
to reverse 78% of rejection episodes [149].  
Augmentation of PP treatment with intravenous immunoglobulin has yielded more 
beneficial effect [66, 69, 149].  
II/8.7. Intravenous immunoglobulin (IVIg) 
Intravenous immunoglobulin preparations isolated from plasma pools of several 
thousand healthy blood donors contain an almost unlimited spectrum of antibody specificities. 
One mechanism by which IVIg may act is to suppress patient panel-reactive antibodies by 
anti-idiotypic antibodies in the IVIg [150]. However, a variety of other potential mechanisms 
have already been proposed that include inhibition of complement activation [151], blockade 
and downregulation of Fc receptors [152], and modulation of T- and B-cell activation and 
differentiation [153].  
II/8.8. Avoidance or postponement of antibody-mediated primary and secondary tissue 
injury  
Anticoagulation therapy. Since antibody-mediated responses are characterized by 
primary endothelial injuries transplant thrombosis is a major pathological characteristic of 
these forms of rejection [154]. Depending on the level of antidonor antibodies, antibody-
mediated post-transplant thrombosis may result in vascular narrowing or occlusion. On the 
basis of the hypothesis that preventing clot formation may postpone graft rejection, 
anticoagulant therapy has been used to treat humoral rejections [155]. Recently, in 
combination with other antibody depletion or suppression treatment, anticoagulation therapy 
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reduced hyperacute/acute rejection episodes enabling ABO-incompatible transplantation with 
satisfying long-term graft survivals [138]. 
 
II/8.9. Glucocorticoids 
Glucocorticoids are by far the most widely used agents to inhibit inflammatory 
responses associated with graft rejection. Although glucocorticoids may induce B-cell 
apoptosis [156] and alloantibody production, they primarily reduce infiltration of the 
parenchyma inflammatory cells by inhibiting the functions of elements of the nonspecific 
immune response including production of and responses to cytokins [157]. Because of its 
strong immunosuppressive and anti-inflammatory effects, glucosteroid is still in the first-line 
for transplant rejection. It is also a major component of maintenance immunosuppressive 
regimens. However, steroid therapy has many side effects, including fluid retention, weight 
gain, diabetes, and bone mineral loss, its benefits must be balanced against the serious, 
sometimes fatal, adverse reactions. 
II/8.10. Proteosome inhibitors, a new therapeutic approach 
Perry et al. has recently described a proteosome inhibitor. Two patients were treated 
with bortezomib for AMR after kidney transplantation. They demonstrated a transient 
decrease in bone marrow plasma cells suggesting persistent alterations in alloantibody 
specificities. They concluded that proteosome inhibition leading to plasma cell apoptosis and 
inhibition may represent a new technique for controlling antibody production in vivo [158]. 
II/9. Prevention of AMR 
 The principal methods of monitoring for rejection are periodic laboratory 
examinations and/or protocol biopsies. However, some evidence suggest that HLA antibodies 
may appear before there is an increase in the serum creatinine [21], suggesting the utility of 
routine testing for HLA antibodies. At any time after transplantation, approximately 20% of 
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patients can be expected to have HLA antibodies [21] and subjects are more likely to have 
grafts that fail as a result of humoral rejection. Ongoing humoral rejection is not apparent by 
laboratory indexes until the organ parenchyma is injured to some critical level, after which 
more difficult to reverse the process. The effectivity of PP and monoclonal antibodies such as 
rituxmab for treatment of chronic rejection remains to be seen. A drug treatment regimen that 
reduces antibodies would be the method of choice. An example to control DSA production is 
the use of FK 506 and MMF, as described by Theruvath et al. [159]. Drugs specifically aimed 
blockade of synthesis or reduction of antibodies require development. An important 
consequence of the humoral theory of chronic rejection is that if antibodies are not found, 
then immunosuppression might be reduced until production of antibodies begins. Many 
patients may be currently overimmunosuppressed, but we have no way of knowing which 
patients can be safely weaned from their current levels. If we can depend on circulating HLA 
antibodies to be a good test of responsiveness, decisions on drug levels can be based on it. It 
should be mentioned, however, that monitoring for HLA antibodies is likely not to be 
comprehensive because other antibodies, such as the MIC, Angiotensisn II system, may also 
be involved. Assays for MIC antibodies are just now being developed and becoming widely 
available. Interestingly, the blood group A and B antigens seem to be different from HLAs 
because ABO-incompatible patients have slightly, but not significantly, lower long-term graft 
survival compared with those with ABO-compatible grafts [138]. 
 
 
 
45
II/10. Our experience, the impact of rituximab therapy for treatment of antibody 
mediated rejection 
II/10.1. Introduction 
The retrospective analysis presented in my thesis compared the outcomes of a 
plasmapheresis (PP)-based versus a PP plus rituximab regimen to treat patients experiencing 
AMR and resistant to steroid plus anti-lymphocyte globulin treatments.  
II/10.2. Materials and methods 
Clinical management: 
This retrospective review describes the clinical courses of 54 (9.5%) kidney transplant 
patients who were treated for AMR at the University of Texas, Division of Immunology and 
Organ Transplantation between 2001 and 2006, a period during which 568 grafts were 
performed. This experience included 26 patients who received PP plus rituximab (Rituxan, 
Genentech Inc., South San Francisco, CA, USA; Group A) which was initiated after the 
inferior experiment results among an initial 28 patient cohort who underwent PP without 
rituximab (Group B). Group B patients more frequently had been supplemented with 0.5 
gm/kg IVIg (Sandoglobulin, Novartis, Basel, Switzerland) or CytoGam (Genesis 
BioPharmaceuticals, Inc. Scarborough, Ontario) than those in group A, because their serum 
IgG levels drifted below 694 mg/dL or their IgM levels, below 60 mg/dL the lower limits of 
normal values in the clinical laboratory. 
All renal transplants were performed following a negative cross-match by complement 
dependent cytotoxicity (CDC) enhanced with antihuman globulin (CDC-AHG) and flow 
cytometry using a fluorescein conjugated anti-human immunoglobulin reagent (One Lambda, 
Inc. Canoga Park, CA). Anti-Class I and Class II HLA PRA determinations were performed 
 
 
46
before transplantation on all patients using CDC-AHG and flow cytometry techniques (One 
Lambda, Inc; FLOWPRA Screening Test; [160, 161]). DSA was also evaluated by microbead 
technology in flow cytometry with goat anti-human IgG-phycoerythrin (One Lambda, Inc 
FLOWPRA Specific Antibody Detection Test; combined single antigen kits (LS1AO1;AO2) 
[160, 161]. 
A similar distribution of induction therapies was observed: namely, Simulect 
(Novartis, Basel, Switzerland), a chimeric mouse-human anti-CD25 antibody (20 mg iv. on 
days 0 and 4; n=15) or for presensitized (PRA > 25%), African-American or re-transplant 
patients, Thymoglobulin (Genzyme, Boston, MA; 1.5 mg/kg, n=39). De novo baseline 
immunosuppression included: cyclosporine (CsA) + sirolimus (SRL) + prednisone (n=33); 
sirolimus + Mycophenolate mofetil (MMF) + prednisone (n=1); CsA + MMF + prednisone 
(n=9) or SRL + prednisone (n=11). CsA and SRL doses were adjusted based upon 
concentration monitoring [162], whereas the starting doses of MMF (2 grams/day) were 
reduced in the presence of adverse reactions. All antibody-treated patients were prescribed 
gancyclovir for 3 months. Every subject received chronic therapy with trimethoprim-
sulfamethoxazole. 
Diagnosis of AMR: 
AMR was diagnosed when a sudden, rapidly progressive bout of renal dysfunction 
occurred particularly early after the transplantation in the absence of positive findings on 
ultrasound, renal scan or urinalysis/cultures which demonstrated another condition: Clinical 
criteria. All patients underwent a renal biopsy which was stained with hematoxylin-eosin or 
periodic acid-Schiff and Masson trichrome reagents. In most cases it showed a characteristic 
histologic appearance based upon the recent modification of the Banff 1997 criteria [7], 
including capillary-glomerulitis with margination and/or thromboses or transmural arterial 
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inflammation with fibrinoid changes. In addition we sought the presence of C4d deposits in 
peritubular capillaries, or serologic tests showing DSA to establish the diagnosis. Beginning 
in 2001, routine immunofluorescence staining was performed on another biopsy sample, using 
fresh-frozen tissue treated with a monoclonal anti C4d-antibody (clone 10–11; Biogenesis, 
Sandown, NH) [6, 9]. The same year testing for donor-specific antibody was implemented. 
However, treatment was initiated for AMR in cases wherein the diagnosis was strongly 
suspected based upon the clinical course, although the histology did not confirm it, albeit C4d 
and/or DSA testing results obtained shortly thereafter established this condition.  
Treatment of AMR: 
Except for 2 subjects in group A, every patient had previously received an initial 
course of anti-lymphocyte antibody therapy for either induction immunosuppression or 
treatment of an acute cellular rejection: Anti-thymocyte globulin (1.5mg/kg/day; n=38); or 
OKT3 (5 mg/day; n=18); or Campath (30 mg/every other day × 2; n=2).  
When refractoriness to the ACR treatment was established, plasmapheresis was 
performed using a Cobe Spectra Continuous Flow Cell Separator (Gambro BCT, Lakewood, 
CO, USA). Prior to each exchange of one plasma volume (range = 2 to 4 L.), the patients 
were premedicated with diphenhydramine hydrochloride. Access and return were obtained 
using a functional arteriovenous fistula (46.4%) or a double lumen central venous dialysis 
catheter (53.6%). The replacement fluid for each procedure was 5% human albumin unless 
the patient was coagulopathic (INR >1.6), or the treatment was performed less than 24 hours 
post-renal biopsy, in which instances, fresh frozen plasma (FFP) was used alone or in 
combination with 5% human albumin. We prophylactically administered 10% calcium 
gluconate to each patient intermittently during the procedures.  
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The typical treatment protocol was a two week course: five daily plasma exchanges 
followed by a two day rest. Thereafter, thrice weekly procedures were performed for two to 
three weeks depending upon whether there had been a reduction of at least 30% in the serum 
creatinine. At the end of each PP cycle, the patients in Group A were administered rituximab 
(Rituxan, Genentech Inc., South San Francisco, CA, USA; 375 mg/m2). Resistance to two PP 
cycles was followed by a third 5-day course which was performed in 16 Group A patients and 
6 Group B patients. During each procedure, the subject was monitored for adverse effects; 
cultures were routinely obtained to search for evidence of bacteremia.  
Data Analysis: 
Figure 9 shows a CONSORT description of the study, indicating the allocation of 
subjects and the two year follow-up. In addition to the clinical and demographic variables of 
gender, ethnicity, age at the time of rejection, donor type (living or deceased), diabetes 
mellitus, number of pre-transplant blood transfusions, cold ischemia time, donor age, donor 
gender, and etiology of ESRD, we compared: graft and patient survivals at two years post-
diagnosis, Class I and II PRA (pre-transplant versus peri-rejection episode), DSA, C4d 
staining, HLA mismatches, time to rejection, Banff classification, serum creatinine and 
calculated GFR by the MDRD formula [26] at the nadir, at the time of diagnosis of rejection 
as well as at 3, 6, 12 and 24 months post-treatment among Group A versus Group B subjects. 
The minimum follow-up was 2 years.  
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Figure 9. CONSORT diagram of the study. 
Statistical analyses were performed on a personal computer using SPSS 13.0 for 
Windows. For normally distributed results the data were summarized as mean values ± 
standard deviations (SD). Continuous variables were compared by the independent sample 
Student t- or ANOVA tests; categorical variables, using cross tabulation calculation or 
Fisher`s exact test. The regression coefficients of the slopes of MDRD GFR values over 2 
years post-treatment were compared by a General Linear Model, Repeated Measures test. We 
estimated graft and patient survivals using the Kaplan-Meier method with significance 
evaluated by the Log-Rank and Breslow tests. A multivariate Cox-regression analysis was 
used to evaluate the impact of treatment components – administration of Rituximab or IVIg or 
the numbers of PP – on 2-year graft survival using all demographic or treatment covariates 
that showed P≤ 0.1 on univariate analysis. 
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II.10.3. Results 
Pre-AHR courses: 
 There was no significant difference in the baseline demographic characteristics of the 
PP (Group B) versus the PP plus Rituximab (Group A) cohorts of the 54 renal transplant 
patients diagnosed with AMR (Table 1). Table 2 describes the early post-transplant clinical 
courses of the subjects. All patients had undergone induction therapy, but there was no 
difference in the proportions of Group A versus Group B subjects treated with anti-thymocyte 
polyclonal globulin or Basiliximab induction therapy. The baseline immunosuppressive 
regimens included significantly more cases treated with CsA de novo among Group B. The 
most striking feature prior to the onset of rejection was a decreased intensity of the 
immunosuppressive regimen by drug withdrawal or dose reduction, frequently associated with 
delayed graft function.  
Table 3 indicates similar methods were employed to diagnose AMR among the 
cohorts, except for the greater prevalence of ACR features observed on pathologic 
examination of biopsies among cohort B, which may have been due to more of these cases 
occurring before the delineation of AMR in the Banff criteria. No significant difference was 
observed comparing the two groups in terms of PRA (Class I and II) pre-transplant or at 
rejection.  The median values of the time to rejection as well as the occurrences of AMR with 
or without ACR did not show significant differences. There were similar fractions of C4d and 
DSA positive cases, despite the fact that many group B patients were diagnosed before the 
availability of these serologic and histologic tools.  
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Features Overall Group A Group B P 
N 54 26 28  
Age (years; mean ± SD) 41.5 ± 11.3 41.5 ± 13.1 41.5 ± 9.4 0.931 
Male (n,%) 24 (44.4) 12 (46.2) 12 (42.9) 0.512 
Source of transplant (n,%)    0.212 
     Living donor 15 (27.8) 9 (36.4) 6 (21.4)  
     Deceased donor 39 (72.2) 17 (65.4) 22 (78.6)  
Ethnicity (n ,%)    0.733 
     White 15 (27.8) 8 (30.7) 7 (25)  
     Black 17 (31.5) 6 (23) 11 (39.3)  
     Hispanic 20 (37.1) 11 (42.3) 9 (32.1)  
     Other 2 (3.6) 1 (4) 1 (3.6)  
PRA, mean ± SD     
     Pre-TX Class I 22.8 ± 29.9 18.7 ± 25.90 26.6 ± 33.2 0.341 
     Pre-TX ClassII 20.2 ± 30.7 17.5 ± 29.5 22.7 ± 32.3 0.541 
HLA-MM (mean ± SD) 4.1 ± 0.2 4.1 ± 0.3 4.1 ± 0.2 0.901 
Diabetes, (n,%)  7 (13) 3 (11.5) 4 (14.3) 0.542 
Prior blood Transfusion (n,%)    0.403 
      0 24 (44.7) 9 (34.6) 15 (53.6)  
     1-3  20 (37) 11 (42.3) 9 (32.1)  
     >3 10 (18.5) 6 (23.1) 4 (14.3)  
Etiology of ESRD (n,%)    0.613 
 Hypertension 20 (37) 8 (30,8) 12 (42,9)  
 Diabetes 1 (1.9) 0 1 (3.6)  
 Hypertension and Diabetes 3 (5.6) 2 (7.7) 1 (3.6)  
 Glomerulonephritis 11 (20.4) 4 (15.4) 7 (25)  
 Polycystic kidney disease 4 (7.4) 2 (7.7) 2 (7.1)  
 Vesico-ureteral Reflux  2 (3.7) 2 (7.7) 0  
 Systemic Lupus Erythematosus 6 (11.1) 4 (15,4) 2 (7.1))  
 Unknown  3 (5.6) 2 (7.7) 1 (3.6)  
 Hepato-renal syndrome 1 (1.9) 1 (3.8) 0  
 Sickle cell disease 1 (1.9) 1 (3.8) 0  
 Alport`s syndrome 2 (3.7) 0 2 (7.1)  
Donor age 36.2 ± 15.7 35.3 ± 14.2 37.03 ± 17.1 0.711 
Male donor gender (n,%) 32 (59.2) 15 (57.7) 17 (60.7) 0.562 
Cold ischemia time (mean±SD) 792.2±115.5 882.4±188.1 718.4±143.6 0.651 
 
1 ANOVA test                
2 Cross tabulation, Fisher’s exact test 
3 Cross tabulation, Linear by linear association, Chi-Square test 
 
Table 1. Demographic characteristics of renal transplant patients treated for AMR. 
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Features  Overall Group A Group B P 
N 54 26 28 
Induction, n (%) 0.231 
    Thymoglobulin 39 (72.2) 19 (73.1) 20 (71.4) 
    Basiliximab 15 (27.8) 7 (26.9) 8 (28.6) 
Baseline IS, n (%) 
     sirolimus/everolimus 44 (81.5) 19 (73.1) 25 (89.3) 0.072 
     cyclosporine 41 (75.9) 15 (57.7) 26 (92.9) 0.042 
     MMF/MPA 10 (18.5) 7 (26.9) 3 (10.7) 0.172 
     Prednisone 54 (100) 26 (100) 28 (100) NA 
     Prograf 3 (5.6) 1 (3.8) 2 (7.1) 0.532 
Decreased 
immunosuppression 
40 (74.1) 15 (57.7) 25 (89.3) 0.0092 
Delayed graft function, n (%) 10 (18.5) 1 (3.8) 9 (32.1) 0.0122 
Maintenance IS, n (%) 
     sirolimus/everolimus 46 (85.2) 25 (96.2)3 21 (75.0) 0.0084 
     cyclosporine 33 (61.1) 15 (57.7) 18 (64.3) 0.754 
     MMF/MPA 15 (27.8) 8 (30.8) 7 (25.0) 0.574 
     Prednisone 47 (87.0) 24 (92.3) 23 (82.1) 0.124 
     Prograf 1 (1.9) 1 (3.8) 0 (0) 0.294 
1 Cross tabulation, Linear by linear association, Chi-Square test  
2 Fisher’s exact test 
3 Data missing on one patient 
4 Kruskal-Wallis non-parametric test comparing distributions between Groups A and B 
 
Table 2. Clinical course of renal transplant patients prior to treatment for AMR. 
 
Treatment regimens for AMR: 
Among cohorts A and B, 14 and 15 patients had experienced an ACR episode prior to 
the diagnosis of AMR, respectively. All patients received initial therapy with monoclonal or 
polyclonal anti-lymphocyte immunoglobulin antibodies at similar mean doses prior to 
recognition and during treatment of the AMR (Table 4). 
Significantly more Group A patients received IVIg (IVIg/Cytogam; Fisher’s exact test, 
P=0.02) as well as a greater number (t-test; P=0.003) and length (t-test; P=0.009) of 
plasmapheresis treatments to treat AMR. Despite these differences, the multivariate analysis 
documented that only the prescription of Rituximab was a major factor to improve outcomes 
(Table 5).  
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Features  Group A 
(n=26) 
Group B (n=28) P 
PRA, mean% ± SD 
     Class I 28.1 ± 29.1 37.9 ± 37.1 0.261 
     Class II 34.9 ± 34.9 35.5 ± 38.6 0.951 
Time to first rejection (days)  
Median (Range) 23 (2-7767) 27 (1-5051) 0.82
2 
Onset<30 days, n (%) 13 (50) 16 (57) 0.403 
Pathological dx of first rejection episode, n (%) 0.024 
     ACR 2 (8) 9 (32) 0.043 
     AMR + ACR 12 (46) 6 (21) 0.083 
     AMR 12 (46) 13 (49) 0.213 
Histopathologic dx AMR 24 (92) 15 (54) 0.053 
DSA positive (n/checked N; %) 16/24 (62) 3/5 (60) 0.523 
C4d positive (n/checked N; %) 22/26(85) 13/20 (65) 0.173       
C4d + DSA + histologic dx 26 (100) 28 (100) 1.03 
PRA = panel reactive antibody; ACR = acute cellular rejection; AMR = acute humoral 
rejection; dx = diagnosis; DSA = donor-specific anti-HLA antibody 
1 ANOVA test 
2 Mann-Whitney U-test 
3 Fisher’s exact test 
4 Cross-tabulation, Linear by linear association, Chi Square test 
 
Table 3. Comparison of metrics for diagnosis of AMR. 
 
To evaluate independent risk factors for 2-year renal allograft survival, a multivariate 
analysis was performed using a Cox regression model (Table 5). The relative risk of graft 
failure at 2 years was 5-fold greater for patients who were not treated with Rituximab; none of 
the other variables showed a significant impact. 
Although Group A underwent significantly more PP treatments, this finding was not 
the major factor determining graft survival (regression analysis, ANOVA test P=0.076). 
 Despite the treatments, 6 subjects in Group A (2 AHR, 2 ACR, 2 ACR/AHR) and 7 in 
Group B (5 AHR, 1 ACR, 1 AHR/ACR) experienced a second episode. Indeed, two subjects 
in each cohort experienced even a third rejection episode.  
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Treatment 
Initial antibody 
Overall Group A 
 
Group B P  
Doses 
P Mean 
values 
Thymoglobulin, (n) 
mg mean ± SD 
(38) 1229.5 ± 
480 
 
(19), 1249.1 ± 458 (19), 1209.9 ± 
513 
 
0.562 0.521 
OKT3, (n) mg 
mean ± SD 
(18) 56.4 ± 27 (5), 56.1 ± 27 (13), 60.6 ± 27 0.032 0.331 
Campath, (n) mg 
mean ± SD 
(2) 92.5 ± 24.7 (2), 92.5 ± 24.7 0 0.212 0.141 
IVIg/Cytogam Total 22 17 5 0.022 NA 
Immunoglobulin 
(Sandoglobulin), (n)  
mg mean ± SD3 
(11) 205.4 ± 151 (7), 217.7 ± 191 (4), 187 ± 47 0.322 0.741 
Cytogam, (n) mg  
mean ± SD3 
(11) 38.5 ± 40 (10), 28.1 ± 21 (1) 142.5 0.022 0.021 
Plasmapheresis      
Mean PP, n ± SD3 17.1 ± 8.3 21.5 ± 8.4 12.1 ± 6.4  0.0031 
Days of PP, n ± SD4 37.4 ± 41.4 52.1 ± 50.8 21.4 ± 18  0.0091 
Rituximab, (n) 
 mg mean ± SD 
NA (94; 3.61) 2385.8 
± 1141 
0 N/A N/A 
Bonferroni correction P=0.01 [163] 
1 Independent sample Student’s t-test 
2 Fisher’s exact test 
3 Mean dose of group—actual total dose for an individual patient varied from 30 to 585 mg 
for IVIg 
4 Mean PP is the number of PP treatments 
5 Days of PP refers to the length of the overall course 
 
Table 4. The therapy for AMR. 
 
Figure 9 shows the consort analysis of the study. Figure 10 shows the graft and patient 
survivals at 2-years. Among the 26 patients in Group A there were 2 therapeutic failures and 
one death due to fungal sepsis in a patient who experienced a third episode and was treated 
with Campath. 
Among the 28 Group B subjects there were 3 deaths - ileus/sepsis, pneumonia/sepsis, 
hepatitis C liver failure - as well as 8 other graft losses due to 3 therapeutic failures, 1 
abandoned graft due to post-transplant lymphoproliferative disease and 4 instances of chronic 
allograft nephropathy. Panel A indicates the patient survival rates among Group A versus 
Group B to be 100 versus 90% (P=NS), respectively. 
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Variable  Univariate 
analysis 
P value 
Multivariate 
analysis P value 
Relative 
risk 
Rituximab 0.009 0.042 5.0 
Pathological dx (Banff)    
     ACR 0.0451 0.51  
     ACR/AHR 0.0541 0.44  
     AHR 0.401 0.30  
     No evidence 0.211 0.40  
IVIg/Cytogam (given vs. not given)  0.051 0.51  
Number of PP 0.0032 0.16  
Age (<40 vs. >40) 0.101 0.32  
C4d (positive vs. negative) 0.421   
PRA Class I (> 30% vs. <30%) 0.741   
PRA Class II (>30% vs. <30%) 0.901   
HLA A,B mismatch ( 0 vs. 1<) 0.401   
HLA DR mismatch (0 vs. 1<) 0.081   
Thymoglobulin (given vs. not given)  0.531   
OKT 3 (given vs. not given) 0.281   
Early rejection (<30 vs. >30 days) 0.491   
Ethnicity (Blacks vs. Others) 0.501   
Diabetes (yes vs. no) 0.771   
Blood transfusion (given vs. not given) 0.241   
Induction therapy  
(Thymoglobulin vs. Simulect) 
0.821   
Re-rejection vs. None 0.401   
Decreased Immunosuppression vs. not 0.781   
Delayed graft function vs. not 0.881   
Sirolimus/everolimus based therapy vs. 
Other  
0.301   
Cyclosporine based therapy vs. Other 0.461   
Donor sex (male vs. female) 0.701   
Donor age (<40 vs. >40 years) 0.601   
Cold ischemic time (<10 vs. >10 hours) 0.7421   
ESRD etiology3 0.5611   
1 Kaplan-Meier analysis 
2 By Independent samples t-test (see Table 4)  
3  Comparing the most frequent reasons for ESRD with Kaplan-Meier analysis: 
 1. Hypertension, Diabetes;  
 2. Glomerulonephritis; 
 3. Polycystic kidney disease; 
 4. Other, less frequent reasons  
 
Table 5. Results of univariate and Cox regression multivariate analyses related to 2 year 
allograft survival. 
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 The respective overall graft survival rates at 2 years were 90 versus 60% for Groups A 
versus B (P=0.005), respectively. Upon multivariate analysis the administration of IVIg or 
Cytogam alone was associated with improved graft survival compared with non-treated, PP 
only subjects (Panel B; 90% vs. 66%, P=0.05). However, administration of Rituximab yielded 
significantly better graft survivals (Panel C; 92% vs. 60%, P=0.009). Even greater outcomes 
were obtained with the combination of Rituximab and IVIg/Cytogam compared with non-
treated, PP only subjects (Panel D; 94% vs. 53%, P=0.025). 
 Neither the slope values (regression coefficients: -0.347 ml/min/month (ANOVA test; 
P=0.29) versus -0.420 ml/min/month (ANOVA test; P=0.25), nor the actual MDRD estimates 
of GFR values (General Linear Model, Repeated Measures test, P=0.42) of group A versus 
group B showed a significant difference over time (3, 6, 12 or 24 months after completion of 
AMR treatment) or between groups. (Figure 11; Table 6). 
Complications of Plasmapheresis:    
 Among the 54 patients who underwent 838 plasma exchange procedures, the 124 
complications occurred in 29 patients, who were similarly distributed between groups A and 
B (Table 7).  No deaths occurred as a result of the plasma exchange procedures, although one 
treatment was discontinued due to severe nausea and vomiting. The most common 
complications were tachycardia (21.8%), bleeding/bruising (16.9%), nausea/vomiting 
(16.1%), pruritus/urticaria (12.9%), hypotension (12.9%), bacteremia (11.3%), and 
hypocalcemia (8.1%).  Other events occurred among less than 1% of subjects.  
There was also no significant difference between the two groups comparing the total 
number of patients with complications (P=0.25 within 3 months and P=0.787 within 6 
months; Fisher’s exact test) and the number with multiple complications (P=0.14 within 3 and 
P=0.17 within 6 months after the completion of treatment; Fisher’s exact test; Table 7). 
 
 
57
 
Figure 10. Kaplan-Meier allograft survival at 2 years post-transplantation treatment for 
rejection. (A) Cumulative patient survival with Rituximab (Group A) and without Rituximab 
(Group B). P=0.09; Log-Rank test. (B) Treatment with IVIg/Cytogam (solid line) and without 
IVIg/Cytogam (dashed line). P=0.05; Log-Rank test. (C) Treatment with Rituximab (Group 
A) and without Rituximab (Group B). P= 0.009; Log-Rank test. (D) Treatment with 
Rituximab + IVIg/Cytogam (solid line) and without Rituximab and IVIg/Cytogam  (dashed 
line) P= 0.025; Log-Rank test. 
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Figure 11.  MDRD GFR over the course of time. Comparison of the evolution of MDRD 
GFR values at 3, 6, 12 and 24 months after rejection treatment. Panel A: Group A; Regression 
coefficient: -0.347 ml/min/months (ANOVA test P=0.29); Panel B: Group B; Regression 
coefficient: -0.42 ml/min/months (ANOVA test P=0.25). 
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MDRD GFR 1,2 Overall Group A. Group B. P 
Baseline (n), mean ± SD 38.4 ± 23.7 37.6 ± 22.9 39.1 ± 24.7 0.82 
At rejection (n), mean ± SD 18.8 ± 16.3 18.0 ± 10.9 19.6 ± 20.3 0.73 
At resolution (n), mean ± SD 44.03 ± 24.1 49.6 ± 23.05 38.7 ± 24.3 0.09 
3 months (n), mean ± SD 42.8 ± 24.9 46.2 ± 23.6 39.8 ± 26.08 0.36 
6months (n), mean ± SD 36.7 ± 26.5 43.4 ± 24.5 30.7 ± 27.2 0.09 
12 months (n), mean ± SD 36.2 ± 27.05 42.0 ± 22.3 31.3 ± 30.01 0.17 
24 months (n), mean ± SD 32.6 ± 29.4 38.3 ± 22.8 28.3 ± 33.3 0.29 
Serum Creatinine, mg/dl3     
Baseline mean ± SD 3.0 ± 2.4 3.1 ± 2.8 2.9 ± 2.0 0.70 
At rejection mean ± SD 5.2 ± 3.2 5.0 ± 3.1 5.3 ± 3.3 0.71 
At resolution mean ± SD 2.1 ± 1.5 2.0 ± 1.6 2.3 ± 1.5 0.45 
3 months mean ± SD 1.9 ± 1.5 1.9 ± 1.3 1.9 ± 1.6 0.86 
6months mean ± SD 1.7 ± 1.5 1.7 ± 1.0 1.7 ± 1.8 0.89 
12 months mean ± SD 1.8 ± 2.1 1.8 ± 1.2 1.8 ± 2.6 0.98 
24 months mean ± SD 1.8 ± 1.9 1.8 ± 1.3 1.8 ± 2.3 0.91 
1MDRD GFR Formula:[26] 
MDRD-GFR (ml/min/1.73m2)=170x[PCr]-0.999 x [age] -0.176 x [0.762 if patient is female] x [1.180 if 
patient is black] x [SUN] -0.170 x [Alb] +0.318          
Where PCr=serum creatinine concentration (mg/dl); SUN=serum urea nitrogen concentration 
(mg/dl); Alb=serum albumin concentration (g/dl). 
2Lost grafts designated as MDRD GFR = 0. 
3SCr values among surviving grafts. 
Table 6. Renal function over time 
In 756 (90.2%) procedures, 5% albumin was used for replacement, while FFP was 
used alone or in combination with albumin in 121 (14.43%). Pruritus and urticaria as well as 
hypocalcemia were exclusively associated with the use of FFP. There was no other significant 
association between the use of 5% albumin or FFP and the various complications (data not 
shown).  
Infectious complication(s) within 6 months showed no significant impact on graft 
survival at 2 years, using the Kaplan-Meier method (P=0.66, Log-Rank test; data not shown). 
Furthermore, there was no significant difference regarding the rates/types of infectious 
complications between the two groups within 3 or 6 months after completion of treatment 
(P=0.24 and P=0.78, respectively; Cross tabulation calculation, Fisher`s exact test). 
Administration of IVIg showed a trend toward decreasing the appearance of infectious 
complications in Group B (P=0.058) but not in Group A (P=0.42; Fisher`s exact test).  
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Type  Overall 
(n=838) 
Group A 
(n=560) 
Group B 
(n=278) 
P 
 
% Patients with ≥ 1 
complication1 
64.8 69.2 57.1 0.722 
Complications, n 124 73 51 0.292 
Tachycardia, n 27 16 11 0.472 
  Bleeding/Bruising, n 21 14 7 0.432 
  Nausea/vomiting, n 20 11 9 0.302 
  Pruritus/urticaria, n 16 11 5 0.402 
  Hypotension, n 16 10 6 0.572 
  Bacteremia, n 14 8 6 0.662 
  Hypocalcemia, n 10 3 7 0.142 
B. Infectious complications 
Type  Overall  Group A Group B 
 < 3 mo < 6 mo < 3 mo < 6 mo < 3 mo < 6 mo 
Patients with an 
infection, n(%) 
17(31.5) 22(40.7) 6(23.07) 10(38.4) 11(39.2) 12(42.8)
Multiple n (%) 9 (16.7) 11 (20.4) 2 (7.7) 3 (11.5) 7 (25) 8 (28.6) 
Upper respiratory, n 2 3 2 31 0 0 
Skin, n 5 10 2 4 3 6 
Wound, n 6 11 1 3 5 8 
Lower respiratory, n 4 8 1 1 3 3 
Urinary tract, n 5 5 3 4 2 5 
Diarrhea, n 1 1 0 0 1 1 
Sepsis, n 3 3 0 0 3 3 
Total number of 
infections 
26 41 9 43 17 26 
Viral infections, n 4 6 2 4 2 2 
Bacterial infections, n 21 32 7 11 14 21 
Fungal infections, n 1 3 0 0 1 3 
1 Number of complications / Total number of PP 
2 Fisher’s exact test 
Table 7. Complications of plasmapheresis treatments. 
 
II/10.4. Discussion 
 Kidney transplant rejection is a multifarious process. Although T cells are usually 
implicated in the acute rejection process, a more pernicious form, resulting in a greater rate of 
early loss or reduced long-term graft survival, [6, 8, 63-65] is mediated by humoral 
antibodies—acute antibody-mediated rejection. This syndrome includes sudden, progressive 
deterioration of renal function is associated with the presence of vascular lesions and/or C4d 
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deposition along peritubular capillaries in a graft biopsy, a positive post-transplant cross-
match or DSA.  The biopsy may not be consistent since the process may be patchy and the 
sampling is limited. Furthermore, the lack of detectable C4d does not exclude mediation by 
non-complement-dependent antibody vectors such as those dependent on cell-mediated 
cytotoxicity. Finally, the DSA may not necessarily be positive [87], because it is measured 
with beads coated with prototypic but not necessarily donor-type HLA A, B or DR but not 
HLA-DP or DQ antigens. In addition, even the cross-match may not be positive, since the 
AMR may be directed toward non-lymphoid, polymorphic tissue-specific antigens [30]. 
Future prospective studies must examine whether a protocol of serial DSA tests 
prognosticates the early and/or long-term outcomes of AMR treatment. 
Patients undergoing AMR tend to be refractory to steroid and anti-lymphocyte 
antibody therapies which are useful for cell-mediated rejection episodes. Based upon 
favorable experiences in inflammatory and autoimmune disorders, plasmapheresis treatments 
have been used to remove humoral mediators from the circulation, although they do not 
suppress antibody synthesis; which often rebounds after cessation of PP [67]. Treatment of 
AMR with IVIg and/or T cell-depleting antibodies in conjunction with PP has yielded 1-year 
graft survivals of 75 to 88% [63-67, 71] and 1-year renal function similar to that observed 
after acute cellular rejection, namely, median creatinine levels of 1.6 to 1.8 mg/dL [8, 64, 66, 
67]. The present series achieved an actual 2-year graft survival rate of 90% among Group A 
patients with serum creatinine values of 1.8 mg/dL. Although the graft survival rate was better 
with rituximab, the level of renal function was only slightly greater for the PP plus rituximab 
group versus the PP alone cohort. Both values were indicative of impairment, suggesting that 
there was incomplete reversal and ongoing immunologic responses; they trended downward 
over time. 
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Beneficial effects of IVIg on B cells have been suggested to result from Fc binding, 
from feedback inhibition of antibody synthesis, and from stimulation of immuno-regulatory 
mechanisms that dampen new IgG synthesis [63]. Jordan et al reported successful reversal of 
AMR in 5 renal transplant recipients who were treated with IVIg in addition to anti-
lymphocyte therapy [68]. Using the combination of PP and IVIg to treat AHR, Lehrich et al 
reported 78% graft survival at 2 years, an outcome that was superior to a PP alone cohort [65]. 
Montgomery et al described an extensive experience with 3-year follow-up of 66 patients 
undergoing AMR treatment with plasmapheresis plus CMV-IgG [69]. Actuarial patient 
survival was 90.4% and graft survival, 78.3%. Herein, we also documented a beneficial 
contribution of either IVIg or CMV-Ig together with plasmapheresis to reverse AMR 
episodes, although the IVIg therapy was only prescribed for patients with low 
immunoglobulin values.    
In this retrospective analysis of our experience, a beneficial effect was observed with 
plasmapheresis in addition to treatment with rituximab, which inhibits B cell proliferation, 
destroys circulating B-cells and induces cellular death through complement binding [161]. A 
number of recent studies have identified the presence of intra-renal CD20 positive clusters, 
without DSA or C4d positivity, to be associated with steroid and/or anti-lymphocyte globulin-
resistant vascular rejection. These cell aggregates, which may serve to present antigen to T- 
cells and generate antibodies that directly injure or coat phagocytic macrophages, have been 
shown to resolve following rituximab therapy [164]. 
Early success with rituximab therapy was described in two case reports: a heart 
transplant [165] and a lung recipient [77]. Alausa et al. reversed refractory acute humoral 
rejection in one kidney transplant case [124]. The benefit of one rituximab infusion plus 
plasmapheresis was reported by Becker et al in 27 patients with biopsy-proven AMR, who 
were resistant to steroid and Thymoglobulin therapy. [17] The reported 2-year graft survival 
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rate was 85%. The diagnosis was based on histological evidence of rejection; DSA or C4d 
immunostaining was not performed. Faguer et al also reported 8 patients successfully treated 
with 4 doses of rituximab, PP, steroid, MMF and tacrolimus. Allograft survival was 81% at 
20 months follow-up. [3] A recently published case report showed a successful outcome of 
Rituximab, PP and IVIg for treatment of AMR in an HIV and hepatitis C virus infected 
patient [166].  
Clinical trials have shown that administration of this antibody for treatment of non-
Hodgkin lymphoma leads to a significant, rapid decline in B cells (70 to 80% decrease) 
followed by full repopulation over the following 12 months [67, 80, 167, 168]. Despite this 
finding, serum immunoglobulin concentrations in this study did not change significantly from 
normal [168]. Interestingly we noted a greater need for IVIg supplementation among the 
rituximab cohort possibly related to the therapeutic reduction in the number of B cells and/or 
to the greater number of plasmapheresis treatments.  
In conclusion, this retrospective study showed a 2-year graft survival of 92% for 
patients treated with rituximab plus plasmapheresis, which was significantly greater than that 
observed among the group who did not receive anti-CD20 therapy. The 100% patient survival 
at 2 years as well as the absence of a greater incidence of major complications among 
individuals treated with rituximab supports the effective, safe use of this monoclonal antibody 
for AMR. Although our data support the primacy of rituximab treatment, the contributions of 
PP and/or IVIg to this outcome must be established in randomized controlled trials. 
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III.  OTHER USES OF RITUXIMAB POST-TRANSPLANTATION FOR LYMPHO-
PROLIFERATIVE DISORDERS (PTLD) 
III/1. Introduction 
Development of lymphoma after renal transplantation was first described by Doak et 
al. [169] in 1968. The term post-transplant lymphoproliferative disorder or disease (PTLD) 
was introduced by Starzl et al. in 1984 [170]. PTLD has been broadly defined as a benign or 
malignant lymphoid proliferation that develops as a consequence of pharmacological 
immunosuppression following the solid organ or bone marrow transplantation [171]. Its 
occurrence among engrafted patients is 12- to 20-fold higher than that among the general 
population [172]. The histologic subtypes of PTLD range from early Epstein–Bar virus 
(EBV)-associated polymorphic lymphoid proliferations to EBV-positive or -negative 
monomorphic B-cell or less often T-cell lymphomas (Table 8).  
III/2. Pathogenesis 
The majority of PTLDs are EBV-associated, of B-cell origin, and expressing CD20 
antigen [173]. The pathogenesis of EBV-associated PTLD is linked to T-cell dysfunction. The 
suppressed EBV-specific immune response results in uncontrolled EBV reactivation in adults 
or primary EBV infection in children [173]. Early-onset PTLDs are mainly regarded as EBV-
driven lymphoproliferations that are frequently, though not always, polyclonal or oligoclonal, 
whereas most late-onset PTLDs are true monoclonal lymphoid malignancies that are not 
necessarily associated with EBV infection. The prognosis of the late onset PTLDs is worse.  
[174].  
A special category of patients at particular risk for PTLD development (10- to 50-fold 
increased risk) are EBV-seronegative patients who receive allografts from EBV-seropositive 
donors, consequently leading to primary EBV infection [175]. This is also the main reason for 
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the greater incidences of PTLD in the early post-transplant period among paediatric 
recipients, who more often are still EBV-seronegative at the time of transplantation. 
Correlations of morphologic and molecular features of PTLDs have contributed to 
recognition of specific disease categories and have provided prognostic indicators for these 
disorders [176]. The outcomes of monoclonal B-cell PTLDs depend upon the interwal from 
transplantation, the histologic features, and the site of lzmphoma origin. 
 
Table 8. World Health Organization classification of post-transplant lymphoproliferative 
disease (PTLD)[177]. 
1. Early lesions 
-Reactive plasmacytic hyperplasia 
-Infectious mononucleosis-like 
2. Polymorphic PTLD 
3. Monomorphic PTLD 
-B-cell neoplasms 
-Diffuse large B-cell lymphoma 
-Burkitt/Burkitt-like lymphoma 
-Plasma cell myeloma 
-Plasmacytoma-like lesions 
-T-cell neoplasms 
-Peripheral T-cell lymphoma 
-Other types 
4. Hodgkin-like PTLD 
 
 
Oncogenic viruses known to be involved in PTLD pathogenesis include EBV and 
HHV-8, which act through direct mechanisms. The virus directly infects the tumor clone 
exerting B-cell transformation. Viral infections exploit several strategies to ensure persistent 
infection: namely, prevention of death of infected cells, enhanced proliferation to maintain the 
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infected reservoir, and evasion of the immune system [178-180]. Several lines of evidence 
have suggested that EBV infection has a major pathogenetic role in PTLDs: (a) EBV infects  
60%–80% of PTLD patients, including 100% of early-onset cases [181]. (b) In many cases of 
monomorphic PTLD, EBV infection is monoclonal, consistent with the hypothesis that the 
virus was present in tumor progenitor cells since the early phase of clonal expansions. (c) A 
decrease in EBV-specific cytotoxic T lymphocytes (CTLs) and an increase in the EBV viral 
load are strongly associated with PTLD development [182]. (d) Treatment of PTLDs with 
autologous EBV-specific CTLs controls viral load and reduces tumor size. 
 An interesting observation in this respect is the strong relationship between EBV-
infected proximal tubular cells of the transplanted kidney (chronic EBV nephritis), even 
months before the onset of PTLD, and subsequent localization of the PTLD in or near the 
graft [183]. It has been suggested that chronic EBV infection of renal proximal tubular cells 
evokes a cellular immune response that not only damages the graft interstitium, but also leads 
to a local inflammatory environment thereby facilitating PTLD development [184]. It is 
unknown whether other viruses, such as the oncogenic BK virus (frequently observed in 
kidney transplant recipients [185]) might also contribute to the development of PTLD as a 
result of providing a local inflammatory environment. It would be of interest to study this 
relationship in the next future. 
The greatest risk of developing PTLD occurs during the first year after transplantation 
[186, 187]. Among solid organ transplant recipients, the median time of onset of PTLD is 
about 6 months [187, 188]. In bone marrow transplant recipients, the median time to onset is 
about 2 months and these patients tend to have widespread, rapidly progressive disease [188]. 
The frequency of PTLD varies depending on the type of transplant and the level of 
immunosuppression. There seems to be a relationship between the occurrence of PTLD and 
treatment of rejection episodes with increased immunosuppression [189]. An analysis of 3796 
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solid organ transplant patients revealed that the highest frequency of PTLD was in lung 
(8.2%) and the lowest frequency (1.3%) in renal transplant patients [187] with 3% among 
liver and  5% among heart recipients [189]. Within a group of 2030 patients after renal 
transplantation, a greater level of immunosuppression was associated with an increased risk of 
developing PTLD [190]. About 30% of pediatric patients can develop PTLD after small 
intestinal transplantation [113]. 
The typical evolution of disease occurs in patient on calcineurin inhibitor therapy who 
suffers a rejection episode which either does not respond to steroid or rapidly relapses after 
tapering steroids, requiring treatment with one or two courses of antilymphocyte globulin or 
OKT3. Shortly thereafter the patient develops PTLD [189]. Interestingly, induction therapy 
with the more recently introduced interleukin (IL)2-receptor antibodies does not seem to lead 
to a higher incidence of PTLD [191]. The total amount of immunosuppression for induction 
or anti-rejection therapy rather than the use of a single maintenance agent has been correlated 
with an increased risk of PTLD [191, 192]. 
 A genetic predisposition may also play a role in the development of PTLD. Patients 
with an inherently lower immune capacity might be at an increased risk for PTLD 
development [193]. For example, subjects with a low capacity to produce cytokines due to 
genetic polymorphism (interleukin-2 and interferon-c), have been reported to display an 
increased risk of PTLD development [194]. 
 Another report suggested that increased levels of IL-10 might be predictive for PTLD 
risk [195]. Although the exact relationship between IL-10 and the development of PTLD has 
not been fully elucidated yet, IL-10 can act as a putative autocrine growth factor for EBV-
transformed B-cells [196].  
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Furthermore, increased total numbers of HLA mismatches have also been observed to 
be associated with PTLD development [191] presumably due to excessive 
immunosuppression relative to the antigenic disparity. 
III/3. Clinical manifestations 
Clinically, PTLD can present in a number of ways: 
1. oropharyngeal hyperplasia or lymphadenopathy which resembles infectious 
mononucleosis, 
2. a fulminant, rapidly progressive polyclonal lymphoid hyperplasia, 
3. Or most commonly as a single or metastatic polyclonal or clonal tumors which most 
often is observed in an extranodal locations within the brain, gastrointestinal tract, or 
allograft [197]. 
The fulminant form of PTLD is characterized by peripheral lymphadenopathy, severe 
metabolic acidosis, organ failure or allograft dysfunction [198]. Approximately 90% of 
patients show an association of active EBV infection, either primary or by reactivation [189]. 
Early changes of PTLD represent, a spectrum of EBV driven lymphoid B-cell proliferations 
arising as polyclonal expansions of EBV infected cells, which progresses to a monoclonal, 
monomorphous B-cell lymphoma [189]. 
In some instances proliferating B-lymphocytes have been shown to be of donor origin 
apparently originating from “passenger” lymphocytes [199]. PTLD development within the 
allograft is higher (30%) in the first post-transplant year among kidney and lung transplant 
recipients [200]. These lymphomas may result from EBV-infected donor B-lymphocytes 
transplanted within the graft escaping host surveillance, due to immunosuppression [201]. 
Consistent with this hypothesis, PTLD of donor origin tends to arise early after 
transplantation and is more often localized in or near the allograft, and rarely shows 
dissemination as compared with recipient-derived PTLD [202]. 
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The polyclonal type is commonly polymorphous but many have been shown to have a 
monoclonal component by genotypic analysis. In some cases different monoclonal and 
polyclonal populations are present in the affected organs or sites [203].  
Overall, the mortality rate for PTLD has been estimated to be 40-70% after solid organ 
[175] and 80% after bone marrow transplantation [177]. A multivariate model for predicting 
survival using three adverse factors including poor performance status (response to therapy 
and tolerability of therapy), monomorphic disease, and graft organ involvement has been 
developed recently [204].  
III/4. Diagnostic methods 
The diagnosis is usually established from biopsy material obtained from patients 
suspected of having PTLD or a rejection episode. Fine needle aspiration biopsy also can be 
sensitive for the diagnosis when reviewed by experienced cytopathologist [205]. Grossly, 
PTLD usually presents either as a tumor mass or an infiltrating lesion indistinguishable from 
other lymphomas. PTLD is characterized by a dense inflammatory infiltrate with a spectrum 
histologically ranging from that found in infectious mononucleosis to that of lymphoma [197, 
203].  
1. Early reactive-like lesions manly involve the oropharynx and lymph nodes with 
preservation of nodal architecture. They may be difficult to differentiate from simple reactive 
hyperplasia. The lesions contain evidence of multiple EBV infections without alterations of 
oncogenes or tumor suppressor genes [206]. 
2. Polymorphous B-cell hyperplasia and lymphoma produces effacement of lymph node 
architecture and dense lymphoproliferative infiltrates of many organs often with associated 
extranodal necrosis. The infiltrate shows a full range of B- and T-cell phenotypes ranging 
from immature to mature lymphocytes. There may be extensive necrosis associated with 
numerous neutrophils and histiocytes are seen. Most cases are monoclonal although rarely 
 
 
70
polyclonal lesions are seen as well. The lesions usually contain a single form of EBV but lack 
oncogene (c-myc, ras) and tumor suppressor gene (p53) alterations [206]. 
3. Monomorphous, monoclonal lymphomatous infiltrates have the features of high-grade 
lymphomas. The monomorphous infiltrate consists of large atypical B-cells, frequently with 
immunoblastic features. They may also show extensive necrosis. The monomorphous 
infiltrate contains a single form of EBV but unlike the polymorphous PTLD it contains 
oncogene (c-myc, c-ras) and tumor suppressor gene (p53) alterations [207]. On rare occasions 
T-cell lymphomas have been observed in this category[208]. 
Analysis of EBV is especially useful for the diagnosis of early cases of PTLD. Early 
detection of EBV DNA in peripheral blood leukocytes or plasma uses quantitative polymerase 
chain reactions (PCR) to indirectly identify patients at risk for PTLD and to monitor 
responses to therapy. PCR assays include those EBV DNA, for in situ hybridization to EBV 
RNA (EBER-1) or for EBV latent membrane protein (LMP) have been used to identify 
patients at risk for PTLD, especially in the pediatric and allogeneic bone marrow transplant 
populations [209]. These two patient populations are particularly at high risk for PTLD, given 
the lack of EBV immunity in most pediatric patients and the high level of immunosuppression 
and the altered immune system seen in T-cell depleted or mismatched allogeneic bone 
marrow transplants.  
 Among pediatric liver and bone marrow transplant patients, EBV PCR has been 
shown to identify patients at risk for PTLD, allowing that early intervention such as 
reductions in immunosuppression or treatment with EBV cytotoxic T cells [210, 211].  
A recently conducted retrospective analysis [209] has also reported the importance of 
peripheral blood EBV PCR for the diagnosis and monitoring of post-transplant 
lymphoproliferative disorder among adult solid organ transplant patients. Peripheral blood 
leukocytes obtained from 35 subjects were tested by EBV PCR at the time of initial 
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evaluation and serially thereafter. Eighteen of 35 (51%) patients were ultimately diagnosed 
with a post-transplant lymphoproliferative disorder by tissue biopsy. Fifteen of 18 (83%) 
patients showed EBER-1 positive tumors by in situ hybridization. EBV PCR was positive in 7 
of 15 patients, suggesting a sensitivity of 39%. Among 17 patients without post-transplant 
lymphoproliferative disorder and three with EBER-1 negative posttransplant 
lymphoproliferative disorder, all displayed negative EBV PCR tests, suggesting a specificity 
of 100%. The authors also reported that declines in EBV DNA load were associated with 
response to therapeutic interventions, such as reduction in immunosuppression, rituximab 
therapy and/or chemotherapy. 
An exact cutoff value of EBV DNA load critical for the development of PTLD in the 
individual patient cannot be defined due to the many variables that may influence the immune 
responses of the individual transplant recipient, such as level of immunosuppression, time 
after transplantation, concomitant infections, type of organ transplanted, but also genetic 
factors. Therefore, an increase in EBV-DNA content in an individual patient is more 
appropriate to identify the risk rather than a cutoff value [212]. 
Analysis of clonality cannot be used to reliably predict tumor behavior in an individual 
patient [189].  To create more confusion in diagnosis and treatment it has been demonstrated 
that lesions at various sites in an individual patient, may show different histologic 
appearances and/or clonality [213]. 
Conventional diagnostic methods are utilized to visualize PTLD include ultrasound, 
endoscopy, magnetic resonance imaging (particularly in case of CNS involvement), computed 
tomography (CT). Positron emission tomography (PET) scanning is increasingly being used 
to visualize malignant lymphomas, especially to detect extra nodal localizations and for post-
treatment evaluation. It has reported to be superior to conventional diagnostic methods for 
differentiation between residual masses containing vital tumor cells versus scar tissue [214]. 
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III/5. Treatment options 
III/5.1. General considerations 
 Early identification of patients with PTLD is important for the treatment of this 
disease, as it allows early intervention. When detected in an early state, reduction in 
immunosuppression is an effective therapy, with response rates as high as 89% among low-
risk patients [187]. There are no large, prospective, randomized trials to provide clear 
guidelines for PTLD treatment. Reduction in immunosuppression (RI) is considered the first 
line therapy [187]. It seeks to reconstitute the immune system. The technique is usually 
tailored to the clinical course of the individual patient and the transplant type. In general, RI 
involves discontinuation of azathioprine or mycophenolate mofetil and minimization of the 
calcineurin inhibitor and steroid. The magnitude of RI is patient-specific and may be limited 
in those with history of organ rejection or when the graft is indispensable for survival. In 
kidney transplant patients, where graft rejection is compatible with life, RI may be aggressive 
including complete cessation of immunosuppression. The time to seek a response to RI is not 
well defined. In one series, the median time to documentation of a response was 3.6 weeks 
[187]. Patients, however, may show signs of clinical improvement within 1–2 weeks. The 
strategy of RI alone can result in high response rates (RR) ranging from 0% to 89% 
depending upon the prognostic factors such as elevated lactate dehydrogenase (LDH), multi-
organ involvement by PTLD, and organ failure at the time of diagnosis [187]. Other 
treatments might need to be used in conjunction with RI if the patient is not a candidate for RI 
alone. 
Targeting EBV by antiviral agents such as ganciclovir or  acyclovir has been 
attempted for prophylaxis and treatment of PTLD [211]. In order to prevent development of 
PTLD, 18 high-risk pediatric liver transplant patients received 100 days of i.v. ganciclovir at 
6–10 mg/kg/ day [211]. None developed PTLD as opposed to the 10% rate of PTLD among 
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an historical cohort of control subjects. In 198 adult patients who received either ganciclovir 
or acyclovir during immunosuppressive therapy with antilymphocyte globulin, only 0.5% 
developed PTLD as opposed to 7% among historical controls [215]. It is difficult to make 
conclusions based on these non-randomized studies since the definition of ‘high-risk’ patients 
and the dosing regimen werse inconsistent. It is unlikely that antiviral agents are effective 
monotherapy to treat PTLD [216]. Latent EBV-infected B-cells, which carry the viral genome 
and express a limited number of viral proteins are not eliminated by antiviral agents. 
However, arginine butyrate, which selectively activates the EBV thymidine kinase gene in 
latently EBV-infected human lymphoid cells and tumor cells, has been used in combination 
with ganciclovir in six PTLD patients, who were resistant to conventional radiation and/or 
chemotherapy [217]. The combination produced complete responses (CR) in four of six 
patients, with a partial response (PR) occurring in the fifth patient. Infusion of patient-derived 
EBVspecific T-cells has been reported for the management of patient with EBV-associated 
PTLD [218]. 
Non-specific immune stimulants such as interferon-alpha can enhance immune system 
in PTLD patients [171, 219]. Since interferon use has the unfortunate side effect of inducing 
allograft rejection, it has not been widely employed. Other treatment modalities such as 
external beam radiation and surgery have been used in settings of localized PTLD [171, 187]. 
Chemotherapy is the standard salvage therapy after failure of reduction in 
immunosuppression, but carries significant mortality and morbidity rates in the organ 
transplant population [220]. Conventional cytotoxic chemotherapy which has been shown to 
be curative for many lymphomas in non-PTLD setting can be administered to PTLD patients 
who fail or are not amenable to RI. In certain aggressive PTLD subtypes (i.e. Burkitt 
lymphoma-like disease), conventional cytotoxic chemotherapy is used as the first line 
treatment as less aggressive approaches appear to be ineffective [221]. Various multi-drug 
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regimens such as CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) have 
been used in PTLD patients. In spite of the high response rate (up to 70%), the associated 
toxicity is significant including treatment-related deaths in about 25% of patients [220, 222]. 
The high mortality of standard chemotherapy regimens in the PTLD population may occur 
because of various factors including baseline pharmacologic immunosuppression, graft 
dysfunction, and colonization with resistant or hospital acquired infectious organisms. 
III/5.2. Monoclonal antibodies for treatment of PTLD 
In the late 1980s and 1990s the initial use of anti-B-cell monoclonal therapy (anti-
CD21 and anti-CD24) demonstrated high response rates with 50% long-term survivals [223]. 
However, these antibodies were not commercially available. In the late 1990s, the anti-CD20 
monoclonal antibody, rituximab, became available world-wide. It has primarily been used to 
treat PTLD [224]. 
Its mechanisms of action have been reviewed in detail earlier are summarized in  
Figure 12.  
 
Figure 12. Rituximab: three potential mechanisms of action include apoptosis, complement 
activation and antibody-dependent cell-mediated cytotoxicity ([171], from Svoboda et al.). 
 
Rituximab was first approved for the treatment of relapsed low-grade CD20-positive 
non-Hodgkin lymphomas with reported overall response rates of up to 50% and complete 
remission rates of 5% [90]. However, the duration of the response in patients with low-grade 
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lymphoma was limited; the median time to progression was 13 months [90]. Since the initial 
approval, it has been widely used as a single agent or in combination with chemotherapy for 
the treatment of various CD20-positive hematological malignancies [93, 225, 226].  
Rituximab also has an expanding role in management of various non-malignant 
diseases, especially autoimmune condition in which B-cells play important role, including 
rheumatoid arthritis [227], Sjogren’s syndrome [228], systemic lupus erythematosus [229], 
myasthenia gravis [230], autoimmune hemolytic anemia [231], idiopathic thrombocytopenic 
purpura [232] and dermatomyositis, polymyositis [233, 234]. The beneficial effect of 
rituximab in antibody mediated rejection episodes has been reviewed earlier. 
In 1998, Fay et al. reported the use of rituximab in a pediatric patient with Fanconi 
disease who developed PTLD 6 months after matched unrelated donor kidney transplantation 
[235]. The patient developed a tonsillar mass and cervical lymphadenopathy. The biopsy was 
consistent with a polymorphic CD20-positive B-cell PTLD. Nearly all B-cell nuclei contained 
EBV RNA and high levels of EBV DNA were detected in peripheral blood. The patient 
received rituximab at the standard dose (375 mg/m2 for 4 weekly doses), experiencing tumor 
regression at only 3 days after the first infusion. He achieved complete response without 
relapse at 6 months [235]. 
Over the recent years many case reports and series described the use of rituximab in 
PTLD [236-243]. Most patients also underwent concurrent RI, some concurrent antiviral 
therapy [241]. Many subjects experienced clinical improvements within a few days of the first 
infusion [240, 242], but in some instances the benefit was not observed for a few months 
[243]. Most patients in the case reports were treated with the standard dose of rituximab (375 
mg/m2) once a week for four consecutive weeks. The majority of the case reports described 
the use of rituximab for early onset PTLD, but suggested that it might also be effective for 
patients with late onset PTLD. Dotti et al. presented five patients who had late onset CD20-
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positive PTLD beyond 2 years after solid organ transplantation. After treatment with 
rituximab [238], 2 patients with advanced disease had only PR, but 3 patients who underwent 
either successful prior surgical debulking or radiotherapy displayed excellent clinical 
outcomes [238]. 
While large retrospective analyses suggested a benefit of rituximab [244-249], Phase 
II trials prospectively confirmed its clinical benefit in PTLD [114, 250, 251]. The RR of 
single agent rituximab treatment in PTLD patients ranged from 44% to 75% with CR rate 
ranging from 28% to 75%. The duration of CR varied depending on the trial, but clearly some 
patients displayed prolonged disease free survivals after single agent treatment. The major 
differences in the results of the phase II trials are likely secondary to the heterogeneity of 
patients enrolled, small sample sizes, and short time of follow-up.  
A large prospective trial using rituximab in PTLD was recently published by Choquet 
et al. [114]. This multicenter, open label, European phase II trial enrolled 46 pediatric and 
adult patients with PTLD after solid organ transplantation who did not improve after RI. They 
were treated with 375 mg/m2 weekly for 4 weeks. Most PTLD cases were of relatively late 
onset; only 14 (35%) patients had a PTLD diagnosis within 1 year after transplantation. At 
day 80, the RR was 44% including 12 (28%) patients with CR. A normal LDH was a 
significant predictor of a response. At day 360, the responses were maintained in 68% of 
patients. The overall survival rate at 1 year was 67%. Rituximab was well tolerated; thereby 
only two grade three to four adverse events related to the treatment [114]. In the USA, a 
smaller phase II trial involving 11 patients revealed a 64% response rate [252].  
Another prospective, multicenter, phase II trial has been published recently [248]. 
Patients were treated with reduction of immunosuppression and four weekly infusions of 
rituximab. Those patients who did not achieve complete remission (CR) received a second 
course of four rituximab infusions. The primary end-point of the study was the CR rate. 
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Among 38 evaluable patients the only severe adverse event was one episode of grade 4 
neutropenia. After the first course of rituximab, 13 (34.2%) patients achieved CR, 8 did not 
respond, and 17 had partial remissions. Among these last 17, 12 were treated with a second 
course of rituximab with 10 (83.3%) achieving CR, yielding an intention-to-treat CR rate of 
60.5%. Eight patients excluded from the trial because of absence of CR were treated with 
rituximab combined with chemotherapy; six (75%) achieved CR. Event-free survival was 
42% and overall survival was 47% at 27.5 months. Fourteen patients died including ten with 
progressive post-transplant lymphoproliferative disorders. The authors concluded that 
extended rituximab treatment obtained a high rate of CR among post-transplant 
lymphoproliferative disorders without increased toxicity, recommending it as initial therapy. 
 A French PTLD Registry prospectively enrolled 230 affected adult kidney recipients 
between January 1, 1998, and December 31, 2003 to analyze the incidence, risk and 
prognostic factors for the disorders. The cumulative incidence of PTLD was 1.18% at 5 years. 
Older age (per year, hazard ratio (HR)=2.19, CI=1.22–3.94) and recipient Epstein-Barr virus 
seronegativity (HR=3.01, CI=1.57–5.08) were associated with an increased risk of PTLD. 
Patients with PTLD showed a reduced survival rate: 61% at 5 years. Graft PTLD displayed 
the best prognosis, namely 81% survival rate after 5 years. Infections with hepatitis C or B 
virus (HCV or HBV), late-onset PTLD, multiple sites of involvement and high Ann Arbor 
staging were risk factors for patient death. Use of azathioprine was associated with a poorer 
survival rate. This incidence and the risk factors among French recipients were consistent 
with international or American PTLD series.  
 The single agent rituximab may be effective to prevent fulminant PTLD. Among 49 
allogeneic bone marrow transplant patients, 17 experienced EBV reactivation as detected by 
positive quantitative PCR, namely, more than or equal to 1000 genome equivalents per 
milliliter. As virus reactivation is believed to correlate with an increased risk of PTLD, these 
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patients underwent ‘pre-emptive’ rituximab treatment [253]. When compared with an 
historical cohort with the same risk profile, this strategy achieved a significant reduction in 
PTLD incidence and eliminated PTLD-associated mortality [253]. A study of 56 allogeneic 
stem cell transplant patients, that included PCR, monitoring of EBV reactivation and of CD8 
positive T-cell immune responses provided indices to initiate rituximab before the immune 
response was overwhelmed by the viral burden [254]. Patients with EBV-specific T cells at 
the onset of reactivation controlled viral reactivation without rituximab. 
Apart from its use as a single agent, rituximab has been reported to have 
chemosensitizing effect on several lymphoma cell lines, possibly by augmenting apoptosis 
[255]. Clinically, patients with CD20-positive non-Hodgkin lymphomas who received 
combination treatment of rituximab with cytotoxic chemotherapy showed superior outcomes 
to those treated with cytotoxic chemotherapy alone [256]. A pilot trial added rituximab to 
cyclophosphamide and prednisone therapy in six solid organ transplant patients [257]. Every 
three weeks they received two to six courses of cyclophosphamide (600 mg/m2, on day 1 of 
each course) and prednisone (1 mg/kg, every 12 h for 10 doses). The first two courses were 
given in combination with 4–6 weekly doses of rituximab (375 mg/m2). At a median follow-
up of 12.5 months (range=4–29 months), all patients responded, including five with CR [18]. 
The one patient who did not achieve CR had a PR, but eventually progressed succumbing to 
fulminant disease. There were no infectious complications; all allografts in surviving patients 
were functional [257]. Preliminary data were presented recently from an ongoing phase II trial 
of sequential rituximab followed by CHOP chemotherapy combined with granulocyte colony-
stimulating growth factor (G-CSF) [258]. Among the 25 evaluable PTLD patients, nine (36%) 
experienced severe infections and three (12%) died of treatment-related causes [258]. 
III/5.3. Rituximab versus chemotherapy 
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Until recently, patients with PTLD who failed RI were treated with cytotoxic 
chemotherapy [259]. There are no prospective, randomized trials that compare chemotherapy 
to rituximab for patients who do not respond to RI. However, a recent retrospective study 
analyzed data on 35 PTLD patients who underwent treatment with rituximab, chemotherapy, 
or both [222]. The findings confirmed that either single agent rituximab or chemotherapy was 
effective treatment for patients who failed RI. Both types of therapies resulted in prolonged 
disease-free survivals and cures in a number of PTLD patients. The 22 patients who received 
rituximab displayed an RR of 68% with 13 (59%) patients in CR. Their median OS was 31 
months. The 23 patients who received cytotoxic chemotherapy had RR 72% with 13 (57%) 
patients in CR at a median OS of 42 months. While rituximab was well tolerated, 26% of 
patients who received chemotherapy died from treatment-related toxicities [222]. An 
important observation in this study was that patients who failed treatment with rituximab were 
subsequently able to receive salvage chemotherapy later [222]. These results suggested that, 
rituximab should be considered a first line treatment for EBV-related, CD-20-positive cases of 
PTLD. 
III/5.4. Case report: successful treatment of post-transplant lymphoproliferative  
disorder and quiescence of dermatomyositis with rituximab and sirolimus 
III/5.4.1. Introduction 
I have presented herein the course of a patient with a chronically disturbed immune 
system owing to dermatomyositis who underwent en bloc pediatric donor renal 
transplantation and subsequently developed PTLD. Our patient was at increased risk for 
PTLD, not only due to antithymocytic globulin (ATG) induction and cyclosporine (CsA)-
based immunosuppression, but also due to the autoimmune disease, which although it 
primarily affects muscle, skin, and lungs, is associated with a greater incidence of 
malignancy. 
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In addition to its efficacy to treat PTLD, rituximab has been reported to be useful for 
reversal of relapses of dermatomyositis, presumably because of its effects to deplete B-cells. 
III/5.4.2 Case history 
A 65-year-old Caucasian woman underwent primary en bloc kidney transplantation 
from a deceased 2-year-old donor on October 23, 2006. The recipient had a history of a 
ruptured arteriovenous malformation in her brain, medication-controlled hypertension, atopic 
dermatitis, dermatomyositis, and asthma. In addition, her history included degenerative disc 
disease, a bout of trigeminal neuralgia, osteoarthritis, and hypothyroidism. She had previously 
undergone a right oophorectomy, appendectomy, knee arthroscopy, arteriovenous fistula 
creation, and removal of a basal cell carcinoma in the left nasolabial crease followed by facial 
and septal reconstruction. The diagnosis of dermatomyositis was obtained after her 
presentation with fatigue, weakness, and myalgia in October 2003. Not only was the creatine 
phosphokinase (CPK) level 4400 U/L, but an electromyogram revealed myopathy of the 
proximal muscle groups. The dermatomyositis had been well controlled for 2 years before 
transplantation using prednisone (5 mg/d) and azathioprine (75 mg/d); CPK levels remained 
in the range of 30 to 60 U/L. Her end-stage renal disease was secondary to autosomal-
dominant polycystic kidney disease. After transplantation, immunosuppressive induction was 
achieved with ATG (100 mg X 3 and 50 mg X 5), followed by inception of sirolimus (SRL; 2 
mg/d), CsA (75 mg AM and 50 mg PM), and prednisone (30 mg/d). She was discharged with 
good renal function, namely a serum creatinine (SCr) of (1.4 mg/dL) 123.7 µmol/l. Shortly 
after transplantation the maintenance regimen was changed from SRL to mycophenylate 
mofetil (MMF; 1 g bid), owing to lower extremity swelling and for putatively better control of 
the dermatomyositis. She continued to experience satisfactory renal function with a SCr of (1 
to 1.5 mg/dL) 88 to 132 µmol/l until July 2007, when her level increased to (2.0 mg/dL) 176 
µmol/l and she offered a history of fever that had persisted for several weeks. The MMF dose 
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was increased from 1 to 1.5 g bid by her rheumatologist who felt that the fever was secondary 
to the polymyositis. She was initially admitted to the transplant center in August 2007 with 
plans for a renal biopsy owing to the elevated SCr. However, the intake history revealed that 
she was injured by a rose bush thorn in February with the onset of cough and then fever soon 
thereafter. Indeed, computed tomography (CT) of the chest performed in July at an outside 
facility was discovered to show pulmonary infiltrates, suggesting an interstitial process or 
pneumonia. Although bacterial cultures were negative, bronchoscopic lavage revealed 
Candida albicans, which was treated with caspofungin (50 mg IV daily for 10 days). Despite 
the relevant antifungal therapy, the fever persisted. Abdominal CT revealed a 6-cm mass in 
proximity to or within the inferior transplanted pediatric kidney. Repeat chest CT as well as 
magnetic resonance imaging of the brain was negative. Histologic and immunochemical 
examinations of an ultrasound-guided biopsy showed a polyclonal-PTLD, which displayed 
EBV and CD20 markers as well as both κ and λ immunoglobulin light chains. The treatment 
strategy for this polyclonal localized neoplasm included replacing MMF and CsA with SRL 
therapy, as well as prescription of oral acyclovir and four weekly intravenous rituximab doses 
(375 mg each). She did not experience an adverse reaction to the treatments; her serum 
creatinine remained in the (1.5 to 2 mg/dL) 132 to 176 µmol/l range and she became afebrile. 
The CPK level was consistently within normal limits (35 to 53 U/L), suggesting that the 
dermatomyositis was not reactivated despite the withdrawal of MMF. In retrospect, 
examination of deceased donor records revealed reactive EBV and cytomegalovirus (CMV) 
immunoglobulin G levels. Unfortunately, there was no information on the recipient’s EBV 
status before transplantation, but the CMV serologies were negative. She had received 
valganciclovir HCl (450 mg daily for 6 weeks) after transplantation because of ATG 
induction therapy and CMV disparity. Two follow-up CT scans at weekly intervals upon 
completion of the rituximab course revealed the size of the mass to be unchanged, prompting 
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a decision for surgical exploration to obtain a biopsy to determine the status of the lesion. At 
operation, a biopsy showed over 90% necrosis of the infiltrating lymphocytes, documenting 
the efficacy of the therapeutic regimen to control the PTLD, although there had been 
emergence of a moderate acute cellular rejection.  
III/5.5. Summary of PTLD and its treatment with rituximab 
The above case report has reported successful treatment of PTLD associated with an 
en bloc renal transplant performed in a patient with a history of recurrent bouts of 
dermatomyositis. What made it unique is the multiple disturbed immune system which 
eventually has led to development of PTLD.  Additional risk factors for malignancy were the 
intense MMF regimen to control the autoimmune disease, the advanced age of the recipient, 
CMV mismatch, and an EBV-positive donor. Rituximab and SRL were chosen due to the 
antibody’s favorable actions on non-Hodgkin lymphomas and dermatomyositis [234, 239, 
260]. This strategy permitted discontinuation of MMF without a relapse of dermatomyositis. 
The effects of the anti-CD20 monoclonal antibody were enhanced by the antineoplastic and 
immunosuppressive actions of the SRL. However, although the combination overcame the 
PTLD and kept the dermatomyositis in remission, it did not prevent the emergence of a 
moderate allograft cellular rejection reaction. In conclusion, this case demonstrated the 
efficacy of rituximab combined with SRL to treat PTLD — over 90% of neoplastic cells were 
necrotic —while suppressing activation of the immunologic comorbidities associated with 
dermatomyositis.  
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Reference Publication Transplant type N Response 
Elstrom et al. [222] Article/retrospective 
analysis 
Solid organ and bone 
marrow (adults) 
 
22 RR was 68% and 13 (59%) 
patients had CR; when compared 
with patients who received 
chemotherapy, the RR was similar 
with less toxicity 
Webber et al. [250] 
 
Abstract/retrospective 
Analysis  
Solid organ (pediatrics) 26 Response rate was 75% and 18 
(69%) patients had CR; four non-
responders included two Epstein–
Bar virus negative one fulminant 
disease, and one Burkitts-like 
disease 
 
Ferry et al. [261] 
 
Abstract/retrospective 
analysis 
 
Bone marrow (pediatric 
and adult) 
 
26 Overall survival (OS) at 180 days 
of 26 patients who received 
rituximab was 46% (vs. 0% for 
seven patients who did not 
received rituximab); patients with 
less advanced disease and low 
viral load had better response rate 
Milpied et al. [249] 
 
 
Article/retrospective 
analysis 
 
Solid organ and bone 
marrow (adults) 
 
32 Response rate was 69% and 20 
(63%) patients had complete 
responses CR; projected OS was 
73% at 1 year; four patients 
relapsed and three died while in 
remission 
Gonzalez-Barca 
et al. [248] 
 
Abstract/retrospective 
analysis 
 
Solid organ (adult) 36 The 36 patients who received 
rituximab had improved OS when 
compared with the total 108 PTLD 
patients (76% vs. overall 21% with 
median follow-up 15 months) 
Morrison et al. [262] 
 
Abstract/phase II trial Solid organ (adults) 8 Response rate was 75% with three 
CRs, three PRs, one progressive 
disease, and one death 
Horwitz et al. [263] 
 
Abstract/phase II trial Solid organ (pediatrics 
and adults) 
 
14 Response rate was 62% (three with 
CRs, five with PRs); one patient 
had stable disease at 1 month; four 
patients progressed on therapy and 
went on to receive chemotherapy, 
resulting in two septic death 
Webber et al. [250, 
252]  
 
Abstract/phase II trial Solid organ (pediatric) 12 Nine (75%) patients had CR, OS 
was 83% with median follow-up 
18 months 
Blaes at al. [252] Article/phase II trial Solid organ (adult) 11 10 months follow-up; RR 64%, 6 
CR, 1 PR, 2 progressive disease, 2 
death; median survival 14 months; 
median duration of CR 10 months 
Oertel et al. [251] 
 
Article/phase II trial Solid organ (adult) 17 Nine (53%) patients achieved CR, 
one with PR, one with progressive 
disease; mean OS 37 months, no 
severe adverse events 
Choquet et al. [114] 
 
Article/phase II trial Solid organ (pediatric and 
adult) 
43 At day 80, RR was 44% with 12 
patients in CR; at day 360, 
responses were maintained 
in 68%; the treatment was well 
tolerated 
 
Table 8. Efficacy of rituximab in the treatment of PTLD in various settings. 
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Many case reports, retrospective analyses, and several prospective trials have 
demonstrated that rituximab is effective for CD20-positive PTLD in various settings (Table 
8). PTLD patients can achieve long-term CR and potential cure after single agent rituximab 
treatment. When compared with cytotoxic chemotherapy, rituximab has comparable RR, but 
significantly reduced toxicity and treatment-associated mortality. Limited data suggest that 
patients with fulminant, advanced disease, EBV-negative or late-onset tumors are less likely 
to respond to single agent rituximab [114, 204, 222, 238, 249]. For these patients, cytotoxic 
chemotherapy might be necessary early in the treatment course. 
For the majority of EBV-associated CD20-positive PTLD patients, rituximab as the 
second line of treatment right after RI is favorable. Given the significant toxicity, 
chemotherapy is best reserved for use in patients who are ineligible or fail rituximab. In the 
future, trials with combination therapies involving rituximab and other immune-based 
treatments as well as early detection and possible prevention will hopefully improve the 
clinical outcome of patients with PTLD. 
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IV. THE ROLE AND EFFICACY OF SIROLIMUS IN RE-TRANSPLANTATION 
IV/1. Introduction  
  Re-transplantation offers a better survival benefit compared with continuous dialysis 
after kidney transplant failure [264].  Patients who lose their first grafts have three options: 
hemodialysis, which results in a poor quality of life and is the least cost effective  [265]; 
peritoneal dialysis which is often complicated by recurrent peritonitis and other intra-
abdominal complications but is cost-effective and allows a more active lifestyle [266]; or 
repeat renal transplantation, which has obvious quality of life benefits, but inherent risks 
relative to graft survival and is expensive at least in the first year [267].   Using the Canadian 
Organ Procurement Registry, Rao, et al [264] observed that, except during the first year 
thereafter, retransplantation conferred a covariate-adjusted reduction in the hazard ratio (HR) 
for mortality compared with dialysis (HR=0.50, P<0.0001).  Despite this benefit, the number 
of patients electing retransplantation is relatively low [268]. In 2003, the United Network for 
Organ Sharing (UNOS) reported that 15.3% of patients awaiting a kidney and 13.5% of those 
receiving a graft had undergone a previous transplantation [1]. One obstacle for these 
candidates to receive a re-transplantation is their higher content of panel reactive antibody 
(PRA) following rejection of the first graft, namely 31.5% of subjects displayed a PRA value 
of at least 20% (Figure 13). 
 
Figure 13. Deceased donor kidney transplants in 2005, by peak PRA at listing. OPTN 
Analysis, November 2006. 
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The outcomes of re-transplantation tend to be inferior to primary grafts (Figure 14). In 
the cyclosporine-prednisone era in 1985,  primary versus second graft survivals at 1, 2 and 5 
years were reported to be 79, 72 and 72% versus 69, 58 and 58%, respectively [269].  In a 12 
year series from Guy’s Hospital (London), the 1, 2, 3 and 4 year survivals of 100 matched 
first renal transplants were superior to 163 re-transplantations, namely 92, 84, 74 and 60% 
versus 82.3, 67.3, 55.97, and 42.14%, respectively [270]. Using more intense recent 
immunosuppressive regimens, the 1, 3 and 5 year survivals reported to UNOS in 2005 were 
95, 89 and 81% versus 93, 83 and 76%, respectively (P<0.01; P<0.0001 and P=0.01) [1].  
Whereas graft failures among both groups in the first year were usually attributed to acute 
rejection and graft thrombosis, thereafter chronic rejection and allograft nephropathy appeared 
to be more frequent among the re-transplant cohort.  
Sirolimus, a potent immunosuppressive drug, inhibits the multifunctional kinase 
mammalian target of rapamycin (mTOR).  In combination with a calcineurin antagonist, 
sirolimus has been shown to reduce the incidence of acute allograft rejection among primary 
renal graft recipients [271-273]. 
 
Figure 14. Unadjusted living donor (LD) and deceased donor (DD) graft survival for first and 
second kidney transplants, 2000–2005. SRTR Analysis, May 2006. 
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Additionally, in vivo animal and in vitro experimental models have demonstrated that 
the drug mitigates intimal hyperplasia and mesangial cell proliferation, suggesting that it may 
prevent the development of chronic allograft nephropathy [274, 275]. Unlike calcineurin 
inhibitors which are known to be nephrotoxic due to vasomotor and tubular toxic effects, 
sirolimus seems to produce only minimal renal injury which has been attributed to inhibited 
mitosis during acute tubular nephropathy. Other features of the drug are its potent anti-
proliferative properties for most rapidly-dividing cells and its blockade of the activities of 
transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF) 
which together contribute to a reduced incidence of malignancies compared with other 
immunosuppressive regimens [276]. 
Until recently, the only high-risk population that had been established to show the 
efficacy of sirolimus was African Americans/Blacks [277], an ethnic group that displays 
inherent adverse genetic, pharmacokinetic, pharmacodynamic, cultural and socio-economic 
factors. In the present study, we sought to examine the outcomes of de novo sirolimus-based 
immunosuppression between high risk retransplant versus primary renal allograft recipients.  
IV/2. Materials and methods 
Patients  
 Between May 1994 and November 2005, a cohort of 162 (15%) subjects underwent 
renal re-transplantation within the overall population of 1,062 grafts at the University of 
Texas, Division of Immunology and Organ Transplantation.  Within this cohort 98 (64%) 
received de novo sirolimus-based immunosuppression. None of the re-transplant patients had 
been previously treated with sirolimus and only 5 had been primarily engrafted at another 
center. The 900 patients who underwent primary transplantations included 576 (64%) who 
were enrolled in de novo protocols of sirolimus immunosuppression.  From these 576 subjects 
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we selected a control population of 200 patients who were matched to the 98 repeat graft 
recipients based upon month of grafting and demographic features (Table 9). 
 Immunosuppressive protocol 
The sirolimus regimen (Rapamune, Wyeth, Philadelphia, PA), generally began with a 
pre-transplant loading dose of 15 mg followed on day 1 with 10 mg once daily. After initial 
adjustment to achieve target trough levels from 10 to 15 ng/mL, the schedule evolved by 6 
months to 10 ± 2 ng/mL for maintenance therapy. Among patients whose grafts displayed 
immediate function, Cyclosporine (CsA; Neoral, Novartis, Basle, SZ) was initiated on day 1 
at reduced doses, 16 employing 50 mg every 12 hours. The exposure was subsequently tailored 
to achieve trough concentrations of 150 ± 25 during the first 6 months, 100 ± 25 from 6-12 
months post-transplant and 50 ± 25 ng/mL thereafter.  Cyclosporine was routinely initiated by 
day 5 even when the patient remained on dialysis.  
The induction and maintenance steroid regimens during the first 90 days for primary 
transplants were tailored according to the perceived risk of a biopsy-proven  acute rejection 
episode (BPAR) based on the organ donor source and the recipient’s immunologic status. 
While low-risk recipients underwent steroid withdrawal at 30 days, high-risk patients were 
delayed until after 90 days.  Steroids were continued indefinitely in all patients who had 
experienced a BPAR or were retransplant recipients.  The addition of mycophenolate mofetil 
(MMF) was necessary only in rare cases, namely, subjects unable to tolerate sirolimus and/or 
CsA. MMF tended to be avoided due to  its apparent potentiation of sirolimus-induced 
myelosuppression and its effects to foster cytomegalovirus (CMV) and BK virus infections as 
well as post-transplant lymphoproliferative disease,  conditions that occurred only rarely 
under sirolimus-based therapy [273, 278]. 
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Five daily doses of Thymoglobulin (Genzyme, Boston, MA. 1.5mg/kg/dose) were 
administered to high-risk recipients from day 0, unless they displayed leukopenia or 
thrombocytopenia in which case we prescribed a 50 to 75% dose reduction or cessation of 
therapy. High-risk patients were deemed to be African-Americans younger than 65 years, 
retransplant subjects, or recipients whose grafts experienced a cold ischemia time greater than 
24 hours. Low-risk patients comprised primary graft recipients who displayed a peak PRA 
less than 20% and were Caucasian, Hispanic, Asian or African-Americans over 65 years of 
age. Induction therapy in low-risk patients utilized basiliximab (Simulect, Novartis, Basle, 
SZ; 20 mg administered at surgery and on post-operative day 4). All retransplant patients 
received thymoglobulin induction and chronic steroid therapy. 
Adjuvant therapy 
All patients were prescribed a first generation cephalosporin (or vancomycin for 
penicillin allergic patients) as a peri-operative antibiotic. Pneumocystitis carinii prophylaxis 
included trimethoprim-sulfamethoxazole (Bactrim SS; orally every other day).  Oral anti-
fungal prophylaxis was prescribed for 3 months as was a course of valgancyclovir for 
prophylaxis for all CMV-mismatched or thymoglobulin-induced patients.  
Clinical follow-up, diagnosis and treatment of rejection 
After hospital discharge patients were seen in the outpatient transplant clinic twice a 
week for the first month, every week for the second month, monthly for a year and every 4-6 
months thereafter.  A complete blood count, basic metabolic panel, and whole blood levels of 
sirolimus and cyclosporine were monitored during each visit using high-performance liquid 
chromatography and a fluorescence polarization immunoassay, respectively.   
When the serum creatinine had increased by more than 30% above the baseline, the 
patient underwent a percutaneous biopsy.  All acute episodes were biopsy-confirmed and 
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graded for severity according to the Banff 1997 criteria with subsequent modifications. Mild 
bouts were treated with pulse steroid therapy alone; moderate or severe ones or those 
refractory to steroids were generally addressed with thymoglobulin (1.5 mg/kg for 10 to 14 
days) or if it was not-tolerated, with ATGAM (Pharmacia, Kalamazoo, MI), or OKT3 
(Orthoclone, Johnson and Johnson, Raritan, NJ). Antibody-mediated acute rejections were 
treated by a 14-day course of thymoglobulin together with at least two 5-day cycles of 
plasmapheresis accompanied by injections of anti-CD20 monoclonal antibody (Rituxan, 
Roche, Basle, SZ).  The diagnoses of chronic rejection (CR)/chronic allograft nephropathy 
(CAN) were established by biopsies performed to establish a cause for renal dysfunction. 
Statistical Analyses 
The database included patient demographic features, post-operative clinical 
conditions, serial serum creatinine concentrations, acute and chronic rejection incidences, as 
well as graft and patient survivals. Median values and ranges or mean values and standard 
deviations of continuous variables were analyzed by independent sample Student’s-t tests.  
Percentage incidences of categorical features were subjected to Fisher exact chi-square tests. 
Distribution analyses were performed with the cross tab method with Fisher exact tests. 
Univariate analyses were followed by multivariate Cox regression techniques with forward 
and backward, stepwise elimination methods, including all variables that showed P<0.20 on 
univariate analysis. Kaplan-Meier time to event analyses were evaluated by log-rank statistics.  
Results were regarded as significant when P<0.05.  
IV/3. Results 
Demographic features 
Table 9 summarizes the demographic features of both populations.  The majority of 
recipients in both groups were males, and the major source of kidneys was deceased donors, 
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all of whom had experienced brain death. The significant demographic differences between 
repeat versus primary graft recipients included greater average PRA value (21.1 ± 27 versus 
7.3 ± 17%; P=0.001), lower mean age (40.3 ± 1.3 versus 47.4 ± 13.3 years; respectively, 
P=0.001), greater proportion of <3 HLA mismatches (20.2 versus 10%, P=0.042) and more 
pre-emptive transplantations (17.3 versus 9%, P=0.036). The mean times on dialysis prior to 
primary or re-transplantation were about 3 years. There were no significant differences in 
donor/recipient gender or ethnicity or their mismatches; in number of combinations with an 
age disparity greater than 10 years; in mean or distribution of cold ischemia times, as well as 
among the incidences of diabetes mellitus, hypertension or anti-CMV antibody pre-
transplantation. Repeat versus primary recipients had mean post-transplant follow-ups of 65.5 
± 29 versus 64.8 ± 31 months (P=0.85).  
Primary end-points 
Figure 13 reveals that the patient survival rates for primary versus re-transplant cases 
at 1 year (Fisher-exact test; 96 versus 94%; P=0.49) and at 5 years (Fisher-exact test; 88 
versus 86%; P=0.68) were not significantly different (Log-Rank, P=0.68, Panel A). The graft 
survival rates at 1 year (Fisher-exact test; 90 versus 90%; P=0.96) and 5 years (Fisher-exact 
test; 78 versus 77%; P= 0.92) were also comparable (Kaplan-Meier analysis; Log-Rank, 
P=0.98; Panel B).  
Among the re-transplantations the causes of 9 graft losses in addition to the 14 deaths 
with a functioning graft were one case of primary non-function, and eight of CR/CAN.  
Among the primary transplantations, the etiologies in addition to 28 deaths were CR/CAN 
(n=10), primary nonfunction (n=3), surgical complications (n=2), and other medical problems 
(n=3).   
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Re-transplant Primary Tx Feature (n=98) (n=200) P 
Recipient age, years, (mean±SD) 40.3±11.3 47.4±13.3 0.0001a 
       >60, n (%) 6 (6.1) 42 (21.0) 0.001b 
       40-60, n (%) 39 (38.8) 99 (49.5) 0.16b 
       18-39, n (%) 53 (53.6) 59 (29.5) 0.0001b 
Panel Reactive Antibody, % 21.1±27.1 7.3±17.5 0.001a 
     <10, n (%) 53 (54.1) 163 (81.5) 0.001b 
     10-20, n (%) 7 (7.1) 12 (6.0) 0.70b 
     21-50, n (%) 20 (20.4) 15 (7.5) 0.001b 
    >51, n (%) 17 (17.3) 10 (5.0) 0.001b 
HLA mismatch, (mean±SD) 4.1±1.8 4.4±1.6 0.26a 
     <3, n (%) 18 (20.2) 20 (10.0) 0.042b 
       3, n (%) 18 (18.4) 32 (16) 0.177b 
     >3, n (%) 70 (71.2) 148 (74) 0.64b 
No Pre-transplant Dialysis 17 (17.3) 18 (9) 0.036b 
Recipient gender, male, n (%) 54 (55) 123 (62) 0.29b 
Recipient ethnicity, n (%)   0.24a 
     Caucasian 43 (44) 75 (38)  
     African-American 18 (18) 57 (28)  
     Hispanic 32 (33) 55 (28)  
     Other 5 (5) 13 (6)  
Deceased donor source, n (%) 67 (68) 140 (70) 0.43b 
Donor age, years (mean±SD) 33.7±15 35.6±15.7 0.32a 
       >60, n 3 13 0.21b 
       40-60, n 31 69 0.62b 
       18-39, n 64 118 0.30b 
Donor gender, male, n (%) 58 (59.2) 106 (53) 0.28b 
Donor ethnicity, n (%)   0.41b 
     Caucasian 63 110  
     African-American 15 31  
     Hispanic 17 51  
     Other 3 8  
Age mismatch >10 years, n 57 127 0.38b 
Gender mismatch, n 43 101 0.26b 
Ethnicity mismatch, n 45 92 1.0b 
Cold ischemia time, min. (mean±SD) 729.4±609.1 787.2±613.0 0.37a 
     <1440, n (%) 87 (88.2) 168 (84.0)  
     1441-2160, n (%) 9 (9.4) 30 (15.0)  
     >2160, n (%) 2 (2.4) 2 (1.0)  
Diabetes, n (%) 21 (21) 56 (28) 0.22b 
Pre-Tx HTN, n (%) 95 (97) 186 (93) 0.16b 
Pre-Tx CMV, n (%) 74 (76) 150 (75) 0.77b 
Pre-transplant Dialysis Time (mo±SD) 36.0±39.8 31.0±42.2 0.20a 
a. Independent sample Student’s t-test 
     b. Cross tab/Fisher exact test 
 
Table 9. Demographic features of patients undergoing re-transplants versus primary grafts. 
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Figure 13. Patient and graft survivals among first (●) versus repeat (▲) renal transplants  
(A) Percent patient survival (B) Percent graft survival. 
 
Figure 14. Incidence of patients free of a biopsy-confirmed acute rejection episode comparing 
first (●) versus repeat (▲) renal transplants (A) Percent free from acute rejection (B) Percent 
free of chronic allograft nephropathy. 
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The causes of death among the re-grafted subjects were: malignancy (n=3), diabetic 
complications (n=2), sepsis (n=4), pneumonia (n=2), liver failure (n=1), and cardiac 
complications (n=2).  The causes of death among primary recipients were cardiovascular 
(n=5), malignancy (n=1), pneumonia (n=2), ruptured aortic aneurysm (n=1), stroke (n=1), 
sepsis (n=4), adult respiratory distress syndrome (n=1), liver failure (n=1), acute intracerebral 
bleed (n=1), and unknown (n=7). 
Figure 14 shows that the incidences of BPAR (Panel A) and CR/CAN (panel B) were 
similar between the cohorts (Log-Rank, P=0.12 and P=0.99, respectively).  While the curves 
depicting CR/CAN overlapped, the freedom from acute rejection was slightly, albeit not 
significantly, greater for the group of primary grafts. Among the repeat transplants there were 
5 (5%) humoral-vascular rejection episodes compared with 8 (4%) among the primary grafts.  
Four primary and 4 re-transplant patients underwent plasmapheresis—anti-CD20 monoclonal 
antibody treatment (data not shown). 
Multivariate analysis for graft and patient survival of all transplant recipients included 
the significant variables in Table 9 as well as those with P values <0.2, namely, donor gender 
(P=0.059), age >60 years (P=0.066), and pre-transplant diabetes (P=0.17).  A beneficial effect 
on patient survival was observed for age less than 60 years at 2 (P=0.033;HR=0.18) with 
decreased impact at 3 and 4 (P=0.052; HR=0.22 and P=0.052;HR=0.25, respectively); and no 
significance at 5 years. The 5 year graft survival was better among subjects without diabetes 
mellitus (P=0.034; HR=0.307); whereas, an HLA-mismatch <3 showed a trend toward a 
protective effect at 5 years (P=0.076; HR=0.164). 
Factors predisposing to graft or patient loss as well as BPAR: re-transplants 
 Table 10 shows the impact of various clinical features on the outcome of re-
transplantations. Upon univariate analysis the risk factors for graft loss included prior 
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transplant loss within 6 months (P=0.0001), older mean recipient age (P=0.01), occurrence of 
an BPAR (P=0.049) and donor ethnicity (P=0.05).  Upon multivariate analysis, graft loss at 5 
years was significantly increased among recipients who experienced BPAR (P=0.034, HR 
2.42).  Patient survival at 2, 3 and 4 years showed the benefit of recipient age <60 years 
(P=0.033, HR 0.185; P=0.05, HR 0.22; P=0.05, HR 0.22), and at 5 years, the absence of 
diabetes mellitus (P=0.034, HR 0.037). Freedom from an acute rejection episode at 5 years 
tended to be associated with an HLA mismatch <3 (P=0.07, HR 0.164).  None of the other 
factors was significant.   
Factors predisposing to graft or patient loss as well as BPAR: first grafts 
 Table 11 shows a univariate analysis of factors affecting the survivals of first renal 
grafts, revealing the beneficial effects of Caucasian ethnicity (P=0.016); shorter cold ischemia 
time (P=0.03); pre-emptive transplantation (P=0.035); younger mean recipient age (P=0.05); 
and freedom from BPAR (P=0.02). Multivariate analysis for graft loss showed hazardous 
effects of cold ischemia time >24 hours at 1, 2, 4 and 5 years (P=0.034, HR=3.14; P=0.02, 
HR=3.7; P=0.042, HR=2.08; P=0.023, HR=2.20). Only at 5 years was the occurrence of 
BPAR a significant risk factor for graft loss (P=0.049, HR=1.89).  Among patient survival 
data for primary transplantations, age >60 years was a risk factor at 1, 4 and 5 years (P=0.02, 
HR 6.08; P=0.002, HR 3.46; P=0.003, HR=3.42, respectively) and occurrence of an acute 
rejection episode at 1 and 3 years (P=0.023, HR 5.6; P=0.046, HR 2.63, respectively).  None 
of the identified factors were significantly associated with the occurrence of an acute rejection 
episode.   
Graft Outcome               Feature Loss (n=25) Survival (n=73) P 
Recipient age    0.14a 
     18-40. n 11 42 0.68a 
      41-60, n 12 28 0.42a 
     >60, n 2 3 0.066a 
 
 
96
     Mean±SD (years) 48.3±13.1 43.9±12.9 0.01b 
Primary graft loss within 6 
months, n 
6 0 0.0001a 
Occurrence of BPAR, n 11 17  0.049a 
Donor ethnicity, n   0.05a 
     Caucasian 19 44  
     African-American 2 13  
     Hispanic 3 14  
     Other 1 1  
Recipient Gender, n    0.50a 
     Male 14 40  
     Female 11 33  
Recipient ethnicity, n   0.88a 
     Caucasian 16 27  
     African-American 6 12  
     Hispanic 3 29  
     Other 0 5  
Hypertensiond , n 24 71 0.80a 
Cold ischemia time(min)    
     <1440 24 65 0.22a 
     >1440 1 8 0.22a 
     Mean (min±SD) 852.8±650.3 734.9±569.4 0.19b 
HLA-mismatch, n    
     <3 1 17 0.07a 
     3 4 6 0.45a 
     >3 20 50 0.46a 
     Mean (±SD) 4.5±1.4 4.2±1.7 0.14b 
PRA (%), n    
     <10 15 38 0.89b 
      10-20 1 6 0.80b 
     >20-50 3 17 069b 
     >50 6 11 0.25b 
     Mean (±SD) 13.9±24.5 11.2±21.1 0.34b 
Re-exposure Same HLA, n 10  38 0.30a 
Pre-emptive Re-transplant, n   0.31a 
     Yes 5 11  
     No 20 62  
Pre transplant diabetes, n 7 14 0.17a 
Blood transfusion, n 22 66 0.91a 
Donor gender, n   0.059a 
     Male 13 45  
     Female 12 28  
Pre transplant dialysis, n 20 61 0.22a 
Pre transplant CMV (+), n 17 58 0.28a 
a. Cross tab the chi2 exact Fisher for difference in distribution 
b.    Independent sample Student’s t-test 
Table 10. Factors impacting graft loss among second transplantations (N=98).  
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Graft Outcome 
Factor Loss (n=53)  Survival 
(N=147) 
P 
Recipient age   0.016a 
     18-40, n 16 41 0.75a 
     41-60, n 21 78 0.09a 
     >60, n 15 25 0.08a 
     Mean (±SD) 50.44±13.5 46.3±13.13 0.05b 
Donor ethnicity, n   .016a 
     Caucasian 29 81  
     African-American 7 24  
     Hispanic 11 40  
     Other  3 1  
Cold ischemia time, min   .04a 
     <1440 41 131  
     >1440 12 16  
     Mean (±SD) 965.54±677.85 730.44±582.86 0.03b 
Occurrence of ARE, n 17 24 0.02a 
Pre-emptive transplant, n    
     Yes 1 17 0.035a 
     No 52 130  
Recipient Gender, n   0.43a 
     Male 35 88  
     Female 18 59  
Donor Source, n   0.75a 
     Deceased 38 102  
     Living 15 45  
Recipient ethnicity, n   .60a 
     Caucasian 18 58  
     African-American 19 38  
     Hispanic 13 41  
     Other 3 10  
Pre Transplant diabetes, n 18 38 0.26a 
Pre Transplant HTN, n 50 136 0.65a 
Pre Transplant CMV+, n 38 112 0.5a 
HLA mismatch, n  16 0.48a 
     <3 4 23 0.82a 
       3 9 23 0.82a 
     >3 40 108 0.77a 
     Mean (±SD) 4.5±1.44 4.32±1.56 0.50b 
PRA (%)    
     <10, n 41 122 0.37a 
     11-20, n 3 9 0.90a 
     21-50, n 5 10 0.53a 
     >50, n 4 6 0.32a 
     Mean (±SD) 8.9±18.45 6.75±17.17 0.45b 
Blood transfusions, n 24 65 0.89a 
Donor gender, n   0.07a 
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     Male 21 83  
     Female  29 63  
Mean donor age (years±SD) 38.11±16.43 34.68±15.4 0.17b 
a. Cross-tab Fisher’s exact chi2 test 
b. Independent sample Student’s t-test 
Table 11. Factors impacting graft loss among primary transplantations (N=200).  
Renal  function  
The post-transplant serum creatinine levels at 1, 3, 12, 24, 48 and 60 months among 
repeat versus primary recipients were not significantly different (Table 12A).  Kidney 
function at these times were also similar for both populations, as computed by the abbreviated 
MDRD formula, considering lost grafts as GFR=0 ml/min (Table 12B). 
A.  Serial serum creatinine values 
Time Post-TX Re-transplant (n=98) (mg/dl) µmol/l 
Primary  (n=200) 
(mg/dl) µmol/l P value 
1 month (2.5 ± 1.8) 221±159 (2.6 ± 2.1) 229±185 0.95 
3 months (1.9 ± 1.1) 168±97 (2.1 ± 1.3) 185±114 0.13 
6 months (2.0 ± 1.0) 177±88 (2.1 ± 1.3) 185±114 0.45 
1 year (1.8 ± 0.8) 159±70 (1.7 ± 0.9) 150±79 0.40 
2 years (2.1 ± 0.9) 185±79 (1.7 ± 1.2) 150±106 0.52 
4 years (1.9 ± 0.7) 168±63 (1.7 ± 1.0)150±88 0.68 
5 years (1.9 ± 0.7) 168±62 (2.0 ± 1.3) 176±114 0.90 
 
B.  Creatinine clearance calculated by abbreviated MDRD 
Time Post-Tx Re-transplants (n=98) 
ml/min/1.73m2 
Primary Tx 
(n=200) 
ml/min/1.73m2 
P value 
1 month 44.7 ± 28.4 43.8± 26.4 0.65 
3 months 52.0 ± 24.2 49.9 ± 26.6 0.37 
1 year 52.0 ± 24.3 52.0 ± 22.1 0.99 
5 years 42.6 ± 16.7 47.0 ± 22.6 0.19 
 
Table 12. Post-operative renal function among re-transplant versus primary graft                 
recipients. 
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IV/4. Discussion 
Allograft survival rates for renal re-transplantations have historically been lower than 
those of primary allograft recipients, particularly beyond 2 years [264, 266, 269, 279-284].  
The 77% survival rate for re-transplantations at 5 years described herein was similar to the 
OPTN report of 76%.  These results demonstrated the efficacy of sirolimus in a second high-
risk population in addition to our prior report among Black recipients [277]. The observation 
that a matched cohort of primary graft recipients showed a 78% graft survival at 5 years 
reported herein, which was lower than the 81% in the recent UNOS report [1], was possibly 
due to the present cohort including our initial experience with sirolimus dating to 1994, when 
we prescribed exposures greater to calcineurin antagonist resulting in potentiation of 
nephrotoxicity. Due to improved understanding of the pharmacokinetic and 
pharmacodynamic interactions between cyclosporine and sirolimus, it now appears that 
greater than 80% reduction in calcineurin inhibitor concentrations de novo yields superior 
results over full [273] or even halved exposure [285]. These effects may have attenuated graft 
survival at five years. 
The present data revealed a low incidence of chronic nephropathy as shown by 
biopsies performed for increases in serum creatinine. The overall level of renal function over 
5 years, albeit stable, was impaired in both groups, namely calculated glomerular filtration 
rates of 40 to 50 ml/min.  We attributed this observation to excessive cyclosporine exposure. 
In an ongoing study of 636 patients employing minimization of CsA dose by 83%, the mean 
4-year GFR calculated by the MDRD formula was 65 ± 24 ml/min/1.78m2 among patients 
treated de novo with <2.5 mg/kg CsA. (Kahan et al, unpublished results), demonstrating that 
optimization of exposures to cyclosporine and sirolimus can result in excellent longer term 
graft function.  
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Improved outcomes of re-transplantation [268] over the past decade may be due to 
several factors. The benefit of uniform administration of thymoglobulin has been shown by 
Ott, et al [286]. However, their acute rejection rate of 44.4% among re-transplant patients 
treated with thymoglobulin induction, tacrolimus, mycophenolate mofetil and corticosteroids, 
was significantly greater than the 28% in the present study. Unfortunately the UNOS database 
does not include the incidence, type or treatment of acute rejection episodes, so that it is 
impossible to judge their occurrence in the general experience versus the 28% among repeat 
versus 22% BPAR among primary recipients in the present study.  Another significant factor 
promoting the success of re-transplantations is the improved methods of cross-matching.  
Additional considerations are the more precise histologic criteria for and tailored therapy of 
BPAR. 
The risk factors detected upon univariate analysis included several that have been 
previously noted to be significant among re-transplant cases: greater degrees of HLA 
mismatch, graft loss within the first 6 months [266], freedom from an acute rejection episode, 
pre-emptive re-transplantation and black donor ethnicity [286, 287].  In contrast, lack of 
sensitization as evidenced by a PRA <10% at the time of re-transplantation was a protective 
factor.  Younger recipient age and absence of diabetes mellitus were significant prognostic 
features for patient survival. However, the use of living donors did not appear to yield better 
results [288].   
Upon multivariate analysis the risk factors for an adverse outcome among re-
transplantation patients were BPAR, age greater than 60 years, diabetes mellitus and HLA 
mismatches ≥3. 
In our experience there was no greater incidence of surgical complications among 
second procedures (data not shown), although this had been previously reported [270].  
Furthermore, we neither confirmed attenuated survivals of repeat kidney grafts among women 
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undergoing second versus first transplantations [279], nor of re-exposure to foreign HLA 
antigens present on the prior graft [284, 289].  Expansion of our experience over the coming 
decade is likely to reveal which of the factors identified on univariate analysis, but not 
confirmed by multivariate techniques, are robust. Furthermore, precisely tailored exposures to 
immunosuppressive drugs with calcineurin inhibitor withdrawal may yield superior long term 
outcomes. 
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V. CONCLUSIONS AND NOVELTIES 
The number of patients awaiting transplantation has been persistently increasing. We 
have sought to improve the outcomes of different aspects of transplantation.  
Substantial proportion of acute and chronic renal allograft rejection processes is 
caused by antibodies reactive to donor antigens. Antibody mediated acute rejection, a newly 
described entity, arises despite ongoing therapy with potent anti-T cell pharmacological 
agents. The detection and treatment of allograft rejection has historically focused upon T-cell 
mediated process and partly because of this humoral mechanisms are less clear. Our goal was 
to examine the influencing factors of AMR and to compare the impact of different treatment 
modalities on the outcomes. 
New findings: 
1. This retrospective study showed a 2-year graft survival of 92% for patients treated with 
rituximab plus plasmapheresis, which was significantly greater (Log-Rank test; p=0.025) than 
that observed among the group who did not receive anti-CD20 therapy.  
2. The 100% patient survival at 2 years as well as the absence of a greater incidence of major 
complications among individuals treated with rituximab supports the effective, safe use of this 
monoclonal antibody for AMR. 
3. There was no significant difference regarding the rates/types of infectious complications 
between the two groups within 3 or 6 months after completion of treatment (P=0.24 and 
P=0.78, respectively). Administration of IVIg showed a trend toward decreasing the 
appearance of infectious complications in Group B (P=0.058) suggesting the beneficial effect 
of it.  
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4. C4d staining and DSA detection and monitoring seem to be very helpful markers for the 
diagnosis of acute antibody mediated rejection. 
In conclusion, our work at The University of Texas, Division of Immunology and 
Organ Transplantation has revealed the primacy of rituximab in the treatment of AMR besides 
the previously established therapeutic effect of plasmapheresis and IVIg. 
Post-transplant malignancy, particularly post-transplant lymphoproliferative disease, 
has become an important cause of mortality since newer, more potent immunosuppressive 
regimens have steadily reduced the incidence of acute rejections and have extended the life 
expectancy of allograft recipients. In this thesis I have reviewed the literature for 
pathogenesis, diagnosis and possible treatment modalities of PTLD. I also have elucidated 
utilization and the efficacy of rituximab in the treatment of PTLD. Majority of EBV-
associated, CD20-positive PTLD patients benefit from rituximab as the second line of 
treatment right after or besides the reduction of immunosuppression. Our successfully treated 
patient also provided evidence for the favorable effect of this treatment modality. Given the 
significant toxicity, chemotherapy is best reserved for use in patients who are ineligible or fail 
rituximab. 
Re-transplantation offers hope for transplant recipients who have had a graft fail. 
Unfortunately such failures, in addition to the suffering they place on the recipient, contribute 
to the overall demand for organs. Given the shortage of donor organs, re-transplantation can 
create tension, especially when outcomes following re-transplantation are below those 
observed for primary recipients.  
New findings: 
1. Upon univariate analysis the risk factors for graft loss included prior transplant loss within 
6 months (P=0.0001), older mean recipient age (P=0.01), occurrence of an BPAR (P=0.049) 
and donor ethnicity (P=0.05). The use of living donors did not appear to yield better results. 
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Upon multivariate analysis, graft loss at 5 years was significantly increased among recipients 
who experienced BPAR (P=0.034, HR 2.42).  Patient survival at 2, 3 and 4 years showed the 
benefit of recipient age <60 years (P=0.033, HR 0.185; P=0.05, HR 0.22; P=0.05, HR 0.22), 
and at 5 years, the absence of diabetes mellitus (P=0.034, HR 0.037). Freedom from an acute 
rejection episode at 5 years tended to be associated with an HLA mismatch <3 (P=0.07, HR 
0.164). 
2. In our experience there was no greater incidence of surgical complications among second 
procedures.  Furthermore, we neither confirmed attenuated survivals of repeat kidney grafts 
among women undergoing second versus first transplantations, nor of re-exposure to foreign 
HLA antigens present on the prior graft. 
3. Patient survival rates for primary versus re-transplant cases at 1 year (96 versus 94%; 
P=0.49) and at 5 years (88 versus 86%; P=0.68) were not significantly different (Log-Rank, 
P=0.68). The graft survival rates at 1 year (90 versus 90%; P=0.96) and 5 years (78 versus 
77%; P= 0.92) were also comparable (Log-Rank, P=0.98).  
4. Incidences of biopsy proven acute rejection and chronic rejection/chronic allograft 
nephropathy were similar between the cohorts (Log-Rank, P=0.12 and P=0.99, respectively). 
Among the repeat transplants there were 5 (5%) humoral-vascular rejection episodes 
compared with 8 (4%) among the primary grafts.   
5. The post-transplant serum creatinine levels at 1, 3, 12, 24, 48 and 60 months among repeat 
versus primary recipients were not significantly different.  Kidney function at these times was 
also similar for both populations, as computed by the abbreviated MDRD formula. 
In conclusion, the novelty of our findings was that a sirolimus-based regimen yielded 
similar efficacy and outcomes among re-transplanted patients compared with first renal 
transplantations with a mean 5-year follow-up.  
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VI. ABBREVIATIONS 
 
Abs - antibodies 
ACR - acute cellular rejection 
ADCC - antibody-dependent cell-mediated cytotoxicity 
ALG - ant-lymphocyte globulin  
AMR - antibody mediated rejection 
AT1R - Angiotensin II type 1 receptor 
ATG - anti-thymocyte globulin 
BPAR - biopsy proven acute rejection 
CDCC - complement-dependent cell-mediated cytotoxicity 
CMV - Cytomegalovirus 
CNS - central nervous system 
CR - complete response 
CTL - cytotoxic T-lymphocytes 
CVF - cobra venom factor 
DAF - decay accelerating factor 
DSA - donor specific antibody 
EBV - Epstein-Barr virus 
FACS - Fluorescence-activated cell sorting 
FDA - Food and Drug Administration (USA) 
FDG-PET - Fluorodeoxyglucose - positron emission tomography 
FK506 - Prograf, tacrolimus 
GC - germinal center 
G-CSF - granulocyte colony-stimulating factor 
HHV-8 – Human Herpesvirus-8 
HLA - human leukocyte antigen 
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LDH - lactate dehydrogenase 
MAC - membrane attac complex 
M-CSF – macrophage colony-stimulating factor 
MHC - major histocompatibility complex 
MIC A and B - Major histocompatibility complex class I chain-related 
gene A and B  
MMF - mycophenolate mofetil 
MZ - marginal zone 
OS - overall survival 
PAS - Periodic acid-Schiff stain 
PCR - polymerase chain reaction 
PR - partial response 
PRA - panel reactive antibody 
PTC - peritubular capillaries 
PTLD - post-transplant lymphoproliferative disorder 
RA - rheumatoid arthritis 
RI - reduction of immunosuppression 
RR - response rate 
SCr - serum creatinine 
SRL - sirloimus, rapamycin, Rapamune 
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